WO2021098394A1 - 样本分析仪及样本分析方法 - Google Patents

样本分析仪及样本分析方法 Download PDF

Info

Publication number
WO2021098394A1
WO2021098394A1 PCT/CN2020/119424 CN2020119424W WO2021098394A1 WO 2021098394 A1 WO2021098394 A1 WO 2021098394A1 CN 2020119424 W CN2020119424 W CN 2020119424W WO 2021098394 A1 WO2021098394 A1 WO 2021098394A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
sample
sedimentation rate
erythrocyte sedimentation
detection
Prior art date
Application number
PCT/CN2020/119424
Other languages
English (en)
French (fr)
Inventor
刘斌
寻文鹏
张广朋
李朝阳
易秋实
叶燚
Original Assignee
深圳迈瑞生物医疗电子股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳迈瑞生物医疗电子股份有限公司 filed Critical 深圳迈瑞生物医疗电子股份有限公司
Priority to CN202080070395.6A priority Critical patent/CN114556081A/zh
Publication of WO2021098394A1 publication Critical patent/WO2021098394A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/05—Investigating sedimentation of particle suspensions in blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/02—Devices for withdrawing samples
    • G01N1/10—Devices for withdrawing samples in the liquid or fluent state
    • G01N1/14—Suction devices, e.g. pumps; Ejector devices
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/726—Devices
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/012—Red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/05—Investigating sedimentation of particle suspensions in blood
    • G01N2015/055—Investigating sedimentation of particle suspensions in blood for hematocrite determination

Definitions

  • This application relates to the technical field of medical equipment, in particular to a sample analyzer and a sample analysis method.
  • the red blood cells are dispersed and suspended due to the flow of blood and the mutual repulsion of the negative charges on the surface of the red blood cells.
  • the red blood cells When the isolated blood is left standing, the red blood cells will sink due to gravity.
  • the type and content of the protein in the plasma will change, which will change the charge balance in the blood, reduce the negative charge on the surface of the red blood cells, and then make the red blood cells form a money-like shape and accelerate the sedimentation. Therefore, the rate of red blood cell sedimentation within 1 hour, that is, the Erythrocyte Sedimentation Rate (ESR), can be used to assist in disease assessment.
  • ESR Erythrocyte Sedimentation Rate
  • ESR is widely used in the treatment and monitoring of infectious diseases, acute and chronic inflammation, rheumatism, connective tissue diseases, cancer and Hodgkin's disease.
  • red blood cell sedimentation rate There are currently known methods for predicting erythrocyte sedimentation rate by measuring the erythrocyte aggregation index. These methods indicate that there is a good correlation between the erythrocyte aggregation index and the erythrocyte sedimentation rate parameter.
  • the red blood cells In order to measure the red blood cell aggregation index, the red blood cells must first be deaggregated, that is, the red blood cells are presented in a single dispersed state, and then the light transmittance change during the aggregation of the single dispersed red blood cells to the aggregated state is measured to obtain the aggregation index or red blood cell sedimentation rate. (ESR).
  • Alifax Company discloses a device that uses a peristaltic pump to depolymerize red blood cells.
  • the peristaltic pump draws blood into the capillary.
  • the peristaltic pump stops immediately and the red blood cells regroup, and the light transmittance curve during the aggregation process is measured.
  • ESR erythrocyte sedimentation rate
  • the blood in order to homogenize the red blood cells, the blood needs to flow through a long capillary tube, which causes the blood to be diluted by the diluent in the capillary tube, which reduces the accuracy of ESR measurement.
  • the measurement accuracy is to be improved in this case, it is necessary to greatly increase the blood volume of the ESR. Due to the high blood viscosity, significant residual loss occurs when blood flows in the capillary tube, and the residual blood loss is proportional to the length of the capillary tube through which the blood flows, resulting in increased cleaning time, cleaning fluid consumption, and contamination rate of the pipeline. At the same time, it also leads to an increase in reagent costs.
  • the purpose of this application is to provide a sample analyzer that integrates routine blood testing and erythrocyte sedimentation rate (erythrocyte sedimentation rate ESR) testing and a corresponding sample analysis method, which can achieve rapid red blood cell depolymerization, thereby achieving erythrocyte sedimentation rate Rapid detection of erythrocytes, and can improve the measurement accuracy of erythrocyte sedimentation rate without increasing blood volume.
  • ESR erythrocyte sedimentation rate
  • the first aspect of the present application provides a sample analyzer, which includes an erythrocyte sedimentation rate detection module, a blood routine detection module, and a sampling distribution module.
  • the sampling and distribution module is configured to collect a blood sample, and allocate a first part of the blood sample to the ESR detection module and a second part of the blood sample to the blood routine detection module.
  • the erythrocyte sedimentation rate detection module includes an erythrocyte sedimentation rate detection pipeline and an erythrocyte sedimentation rate optical detection device.
  • the erythrocyte sedimentation rate detection pipeline is configured to provide a detection place for the first part of the blood sample to be distributed.
  • the first part of the blood sample in the erythrocyte sedimentation rate detection pipeline is irradiated with light, and the erythrocyte sedimentation rate of the blood sample is detected by detecting the degree of absorption or scattering of the light by the first part of the blood sample, wherein the erythrocyte sedimentation rate detection module includes and A first syringe connected to the erythrocyte sedimentation rate detection pipeline, and the first syringe is configured to drive the first part of blood sample to flow in the erythrocyte sedimentation rate detection pipeline.
  • the blood routine detection module includes a routine blood reaction pool and a routine blood detection device.
  • the routine blood reaction pool is configured to provide a place for the second portion of the blood sample to be mixed with reagents.
  • the routine blood detection device is used for The blood routine parameter detection is performed on the blood sample to be tested obtained by mixing the second part of the blood sample and the reagent in the routine blood reaction tank.
  • the second aspect of the present application provides a sample analysis method.
  • the sample analysis method includes a sample distribution step, an erythrocyte sedimentation rate detection step, and a blood routine detection step.
  • the sampling and distribution module collects the blood sample in the sample container, and distributes the first part of the blood sample to the erythrocyte sedimentation rate detection module and the second part of the blood sample to the blood routine detection module.
  • the first syringe of the erythrocyte sedimentation rate detection module sucks the first part of the blood sample into the erythrocyte sedimentation rate detection pipeline of the erythrocyte sedimentation rate detection module, and the erythrocyte sedimentation rate detection module
  • the detection device irradiates the first part of the blood sample with light and detects the degree of absorption or scattering of the light by the first part of the blood sample to detect the erythrocyte sedimentation rate of the first part of the blood sample.
  • the blood routine detection module detects the blood routine parameters of the second part of the blood sample.
  • a syringe as a power device for measuring the red blood cell sedimentation rate, it is beneficial to realize the rapid depolymerization of red blood cells and improve the measurement speed and measurement accuracy of the red blood cell sedimentation rate without increasing the blood volume. , There is no need to use too long erythrocyte sedimentation rate detection pipeline, thereby reducing the detection cost and the cleaning difficulty and cleaning cost of the erythrocyte sedimentation rate detection pipeline. In addition, the use of a syringe can also achieve good compatibility with blood cell analyzers currently used for routine blood testing.
  • Fig. 1 is a schematic structural diagram of a first embodiment of a sample analyzer provided in the first aspect of the present application;
  • FIG. 2 is a schematic structural diagram of a second embodiment of the sample analyzer provided in the first aspect of the present application.
  • FIG. 3 is a schematic structural diagram of a third embodiment of the sample analyzer provided in the first aspect of the application.
  • FIG. 4 is a schematic structural diagram of a fourth embodiment of the sample analyzer provided in the first aspect of the application.
  • FIG. 5 is a detection timing diagram of the sample analyzer shown in FIG. 4;
  • FIG. 6 is a schematic diagram of a liquid circuit structure of the sample analyzer provided in the first aspect of the application.
  • Fig. 7 is a schematic structural diagram of a fifth embodiment of the sample analyzer provided in the first aspect of the present application.
  • FIG. 8 is a detection timing diagram of the sample analyzer shown in FIG. 7;
  • FIG. 9 is a schematic structural diagram of a sixth embodiment of the sample analyzer provided in the first aspect of the present application.
  • FIG. 10 is a detection timing diagram of the sample analyzer shown in FIG. 9;
  • FIG. 11 is a schematic structural diagram of a seventh embodiment of the sample analyzer provided in the first aspect of the present application.
  • FIG. 12 is an absorbance curve diagram of an erythrocyte sedimentation rate detection process of the sample analyzer provided in the first aspect of the present application;
  • FIG. 13 and 14 are different detection sequence diagrams of the sample analyzer provided in the first aspect of the present application.
  • 15 to 17 are schematic flowcharts of different embodiments of the sample analysis method provided in the second aspect of the present application.
  • a sample analyzer including an erythrocyte sedimentation rate detection module 10, a routine blood sedimentation detection module 20, and a sampling distribution module 30.
  • the sampling and distribution module 30 is used to collect blood samples, and distribute the first part of the blood sample (that is, the first part of blood sample) to the erythrocyte sedimentation rate detection line 11 of the erythrocyte sedimentation rate detection module 10 and the second part of the blood sample (that is, the second part of blood).
  • the sample is allocated to the blood routine detection module 20.
  • the sampling distribution module may be configured to distribute the first part and the second part of the blood sample sequentially, or it may be configured to distribute the first part and the second part of the blood sample at the same time, and the distribution order is not limited.
  • the sampling distribution module 30 can allocate the first part of the blood sample to the erythrocyte sedimentation rate detection pipeline of the erythrocyte sedimentation rate detection module 10 by adopting a method of collecting once, distributing in two or by collecting and distributing in two times. 11 and the second part of the blood sample is allocated to the blood routine reaction pool 21 of the blood routine detection module 20.
  • the method of one-time collection and two-time distribution is as follows: after the sampling distribution module 30 collects the blood sample, the sampling distribution module 30 first distributes a part of the collected blood sample (that is, the first part of the blood sample) to the blood sedimentation detection module 10 The erythrocyte sedimentation rate detection pipeline 11, and then distribute another part of the collected blood sample (ie the second part of the blood sample) to the blood routine reaction pool 21 of the blood routine detection module 20, or the sampling distribution module 30 first distributes the collected blood sample Part of the blood sample (that is, the second part of the blood sample) is allocated to the blood routine reaction pool 21 of the blood routine test module 20, and the other part of the collected blood sample (that is, the first part of blood sample) is allocated to the blood sedimentation test of the blood sedimentation test module 10.
  • the method of collecting and distributing in two times is as follows: the sampling and distribution module 30 first collects a part of the blood sample and allocates a part of the collected blood sample to the erythrocyte sedimentation rate detection line 11 of the erythrocyte sedimentation rate detection module 10 or the blood routine of the blood routine detection module 20 The reaction pool 21; the sampling distribution module 30 collects another part of the blood sample and distributes the other part of the collected blood sample to the blood routine reaction pool 21 of the blood routine detection module 20 or the blood sedimentation detection line 11 of the blood sedimentation detection module 10.
  • the erythrocyte sedimentation rate detection module 10 includes an erythrocyte sedimentation rate detection pipeline 11 and an erythrocyte sedimentation rate optical detection device 12.
  • the erythrocyte sedimentation rate detection pipeline 11 is used to provide a detection place for the first part of the blood sample to be distributed, and the erythrocyte sedimentation rate detection device 12 is used to detect the blood sedimentation detection pipeline.
  • the first part of the blood sample in 11 is irradiated with light and the degree of absorption or scattering of the light by the first part of the blood sample allocated to the erythrocyte sedimentation detection tube 11 is detected to detect the red blood cell sedimentation rate of the blood sample.
  • the erythrocyte sedimentation rate optical detection device 12 the first part of the blood sample does not shift in the erythrocyte sedimentation rate detection pipeline 11, that is, remains stationary.
  • the blood routine detection module 20 includes a blood routine reaction tank 21 and a blood routine detection device (not shown in FIG. 1).
  • the blood routine reaction tank 21 is used to provide a place for mixing the second part of the blood sample to be mixed with the reagents.
  • the routine detection device performs routine blood detection on the blood sample to be tested obtained by mixing the second part of the blood sample and the reagent in the routine blood reaction tank 21.
  • the blood routine detection device may be at least one of an optical detection unit, an impedance detection unit, and a hemoglobin detection unit.
  • the blood routine reaction cell may include at least one of an optical reaction cell, an impedance detection reaction cell, and a hemoglobin detection reaction cell.
  • the blood routine testing module 20 When the blood routine testing module 20 performs routine blood testing on a blood sample, the blood sample and corresponding reagents (such as diluents and/or hemolytic agents and/or stains, etc.) can be added to the routine blood reaction tank 21, by The blood routine detection device measures the blood sample in the routine blood reaction tank 21 to obtain at least one routine blood parameter, which can include five classification results of WBC (White blood cell, white blood cell), WBC count and morphological parameters, and HGB (Hemoglobin, hemoglobin) function measurement, RBC (Red blood cell, red blood cell) and PLT (blood platelet, platelet) count and at least one or more combinations of morphological parameters, in the actual routine blood test process, according to needs
  • the increase or decrease of routine blood test items is not limited here.
  • the sample analyzer provided in the embodiment of the application is provided with an erythrocyte sedimentation rate detection module 10 and a routine blood sedimentation detection module 20.
  • the erythrocyte sedimentation rate detection module 10 can detect the erythrocyte sedimentation rate of blood through the erythrocyte sedimentation rate detection pipeline 11 and the erythrocyte sedimentation rate optical detection device 12, and the blood routine detection module 20 It can detect blood routine parameters, so that the sample analyzer provided by this application can detect both the red blood cell sedimentation rate and blood routine.
  • one device can achieve two blood test items with diverse functions. It is more convenient to use.
  • the sample analyzer further includes a liquid path support module 40 for providing liquid path support for the sample distribution module 30, the erythrocyte sedimentation rate detection module 10 and the blood routine detection module 20.
  • the liquid path support module 40 performs liquid path support by providing liquid to the sampling distribution module 30, the erythrocyte sedimentation rate detection module 10, and the blood routine detection module 20.
  • the liquid path support module 40 can provide cleaning solutions to the sampling distribution module 30, the erythrocyte sedimentation rate detection module 10, and the blood routine detection module 20 respectively to clean the sampling needle 31, the erythrocyte sedimentation rate detection line 11, and the routine blood reaction tank 21, respectively. Avoid contaminating the blood sample to be tested, leading to inaccurate test results.
  • the erythrocyte sedimentation rate detection module and the routine blood detection module include reagent sample addition, reaction mixing, measurement actions, cleaning and maintenance, etc., which are all assisted by the liquid path support module.
  • the sample analyzer also includes a control module 50, which is connected to the sampling distribution module 30, the erythrocyte sedimentation rate detection module 10, the blood routine detection module 20, and the liquid path support module 40, respectively, and the control module 50 is used to control the sampling distribution module respectively 30.
  • the actions of the erythrocyte sedimentation rate detection module 10, the blood routine detection module 20, and the liquid path support module 40 so that the sampling distribution module 30, the erythrocyte sedimentation rate detection module 10, the blood routine detection module 20, and the liquid path support module 40 cooperate with each other to complete Detection of erythrocyte sedimentation rate and blood routine parameters.
  • control module 50 may include a processor and a memory.
  • the processor can be a CPU, GPU or other chips with computing capabilities.
  • the memory is loaded with various computer programs for the processor to execute, such as an operating system and application programs, and data required to execute the computer programs.
  • the erythrocyte sedimentation rate detection module 10 further includes a first power device (also referred to as an erythrocyte sedimentation power device) 14 connected to the erythrocyte sedimentation rate detection pipeline 11 and its first end 111 here, and the first power device 14 is provided It is used to drive the first part of blood sample to flow in the erythrocyte sedimentation rate detection tube 11 and make the first part of blood sample flow to the detection area 113 in the erythrocyte sedimentation rate detection tube 11, and then stop moving and keep it still, so that the erythrocyte sedimentation rate optical detection device 12 can control the first part.
  • the erythrocyte sedimentation rate of the blood sample is tested.
  • the first power device 14 is not only used to drive the first part of the blood sample into the erythrocyte sedimentation rate detection pipeline 11, but also to ensure that the blood sample in the erythrocyte sedimentation rate detection pipeline 11 remains stationary during the detection of the erythrocyte sedimentation rate. .
  • the working process of detecting ESR is as follows: the first power device 14 drives the first part of blood sample to flow into the erythrocyte sedimentation rate detection tube 11, when the first part of blood sample flows to the erythrocyte sedimentation rate detection tube After the specific position (detection area 113) of 11, the first power device 14 suddenly stops and instantaneously interrupts the flow of the first part of the blood sample in the erythrocyte sedimentation rate detection tube 11, which causes the first part of blood sample to suddenly decelerate (or stop flowing) at this time ), followed by aggregation and precipitation of red blood cells.
  • the control module 50 is configured to immediately stop the driving of the first power device 14 after controlling the first power device 14 to drive the first part of the blood sample to the detection area 113 of the erythrocyte sedimentation rate detection tube 11, so that the first part The blood sample remains stationary in the detection area 113, so that the erythrocyte sedimentation rate optical detection device 12 detects the red blood cell aggregation rate of the first part of the blood sample, that is, detects the degree of absorption or scattering of light by the blood sample in the detection area, thereby Obtain the red blood cell sedimentation rate.
  • the sample analyzer provided in the embodiment of the present application can limit the length of the erythrocyte sedimentation rate detection pipeline 11, which can not only reduce the volume of the entire instrument, but also reduce the amount of blood and cleaning required for detection and analysis.
  • the amount of cleaning solution used in the erythrocyte sedimentation rate detection pipeline 11 greatly reduces the cost of a sample analyzer that integrates ESR detection and blood routine detection.
  • the first power device 14 may also drive the first part of the blood sample to flow in the erythrocyte sedimentation rate detection tube 11 after detecting the erythrocyte sedimentation rate to discharge the erythrocyte sedimentation rate detection tube 11 in preparation for the next detection.
  • the first power device 14 may be a pump or a syringe or other pressure source that can provide power.
  • a peristaltic pump as the fluid power source of the erythrocyte sedimentation rate detection module will result in a substantial increase in blood consumption.
  • the residual volume of the blood sample during the flow of the detection pipeline increases, which not only leads to waste of blood samples, but also increases the difficulty and amount of cleaning of the detection pipeline, and also increases the crossover. Possibility of contamination.
  • the liquid volume of the peristaltic pump can be large or small, and the accuracy is poor. It is suitable for occasions with low requirements for liquid quantification, but cannot be suitable for the high-precision quantitative (several micro-upgrade) sub-sampling requirements in the field of blood cell measurement.
  • a peristaltic pump as the liquid power source of the erythrocyte sedimentation rate detection module will result in the need to provide two power sources in the sampling distribution module, that is, one for driving the sampling
  • the other peristaltic pump is used as the liquid power source of the erythrocyte sedimentation rate detection module.
  • This is technically difficult when arranging the peristaltic pump and the sampling distribution module, because it is difficult for the peristaltic pump and the sampling distribution module to coexist in the blood analyzer. And it will greatly increase the cost, volume and structural complexity of the all-in-one machine.
  • the first power unit 14 is configured as a first syringe.
  • This structural solution is not only conducive to the rapid and accurate detection of ESR (due to the precise quantification of the syringe, the blood sample can be accurately drawn into the detection area 113 of the erythrocyte sedimentation rate detection pipeline 11), but also conducive to the simplicity of the erythrocyte sedimentation rate detection module 10 And it is integrated into the existing blood routine analyzer at low cost, and basically does not increase or rarely increases the volume of the blood routine analyzer.
  • the sampling distribution module 30 may include a sampling needle 31 and a driving device (not shown).
  • the driving device is used to drive the sampling needle 31 to move, so that the sampling needle 31 collects the blood sample and allocates a part of the blood sample to the blood routine reaction pool 21 of the blood routine detection module 20.
  • the blood sample is usually stored in a test tube 100, and the top of the test tube 100 is provided with a cap for sealing.
  • the driving device drives the sampling needle 31 to move above the corresponding test tube 100, and drives the sampling needle 31 to pierce the cap of the test tube with its needle tip or one end of the needle 311, and then extend into the test tube to suck the blood sample in the test tube to collect blood sample.
  • the sampling distribution module 30 may further include a second power device (also referred to as a sampling power device) connected to the end 312 of the sampling needle 31 away from the needle 311 through the power supply line 32.
  • a second power device also referred to as a sampling power device
  • the power supply line 32 is used to connect the end 312 of the sampling needle 31 far from the needle 311 to the second power device 33
  • the second power device 33 is used to drive the power line 31 through the power line 31.
  • the sampling needle 31 sucks or discharges the blood sample through the needle 311.
  • the second power device 33 is used to provide a negative pressure to the sampling needle through the power supply line 32 to suck the blood sample and to provide a positive pressure to discharge the blood sample.
  • the second power device 33 may be a pump or a syringe or other pressure source capable of providing power, such as a positive and negative air pressure source. It is particularly advantageous here if the second power unit 33 is configured as a second syringe.
  • the first power device 14 and the second power device 33 may be the same power device, especially the first syringe and the second syringe are the same syringe. Since the second syringe used for blood routine quantitative blood separation usually requires a relatively high accuracy, using the second syringe as the first syringe at the same time can not only achieve fast and accurate detection of ESR, but also can further reduce the cost of sample analysis.
  • the second end 112 of the ESR detection tube 11 opposite to the first end 111 may be connected to the end 312 of the sampling needle 31 far from the needle 311.
  • an exemplary specific working process of the blood distribution of the sample analyzer may be: the control module 50 controls the second power device 33 to drive the sampling needle 31 to distribute the second part of the blood sample to the routine blood reaction cell through the needle 311 21. Then control the first power device 14 to draw the first part of blood sample from the end 312 of the sampling needle 31 away from the needle 311 into the erythrocyte sedimentation rate test tube 11, where the first part of blood sample and the second part of blood sample are the same blood Different parts of the sample.
  • the sample collected by the sampling module follows the blood sample circuit during measurement. Flow, first go through the ESR module for ESR measurement, and then go through the cell counting module for routine blood measurement.
  • the blood sample must first flow through the ESR module, and then through the blood routine module, so that the blood sample to be tested for routine blood flow through more diluent areas, leading to the blood sample being diluted and contaminated, resulting in blood routine Inaccurate detection.
  • a part of the power supply pipeline 32 may be the ESR detection pipeline 11.
  • the part of the power supply line 32 close to the sampling needle 31 is set as the erythrocyte sedimentation rate detection line 11.
  • the second power device 33 is preferably used as the first power device 14 and is further used to suck a part of the blood sample in the sampling needle 31 (that is, the first part of blood sample A) into the erythrocyte sedimentation rate detection pipeline 11.
  • the sampling needle 31 still distributes a part of the blood sample (that is, the second part of blood sample B) in the sampling needle 31 to the blood routine reaction pool 21 through the needle 311 to perform blood routine parameter detection.
  • the second power device 33 is reused as the first power device 14, especially the first syringe, and the power supply line 32 of the sampling needle 31 is reused as
  • the erythrocyte sedimentation rate detection pipeline 11 does not need to be additionally provided with a reaction tank and a power device, so the structure is simple and the cost is reduced.
  • the second syringe 33 is respectively connected to the power supply line 32 and the diluent storage portion 35 through the control valve 34.
  • the second syringe 33 draws diluent from the diluent storage portion 35; when the control valve 34 connects the second syringe 33 with the power supply line 32, The second syringe 33 provides suction power or discharge power for the sampling needle 31 through the power supply line 32.
  • the erythrocyte sedimentation rate detection pipeline 11 can be directly coupled to the back-end pipeline of the sampling needle 31, that is, the power supply pipeline directly, which can achieve simplicity without increasing the complexity of the instrument and making the changes as small as possible.
  • the erythrocyte sedimentation rate detection module 10 is integrated into the existing blood analyzer. As shown in the working sequence diagram of FIG. 5, the second power device 33 (especially the second syringe) or the first power device 14 (especially the first syringe) drives the sampling needle 31 to suck the blood sample into the sampling needle 31 Until the blood sample flows into the erythrocyte sedimentation rate detection pipeline 11.
  • the sampling needle 31 for example, first moves to the blood routine reaction pool 21 of the blood routine detection module 20 for blood separation (blood segment B). After the blood separation is completed, it is necessary to ensure that there is still a blood sample (blood segment A) in the erythrocyte sedimentation rate test tube 11 ), or ensure that there is still a blood sample (blood segment A) in the sampling needle 31 that can be sucked to the erythrocyte sedimentation rate detection line 11. Then, the ESR test and the blood routine test are started at the same time or in time sharing, and it is ensured that during the ESR test, the blood sample in the erythrocyte sedimentation rate test tube 11 does not shift. When the test is completed, the pipeline is cleaned. .
  • An exemplary specific working process of the blood distribution of the sample analyzer shown in FIG. 4 is as follows: under the control of the control module 50
  • the driving device first drives the sampling needle 31 to move to the test tube 100 loaded with the blood sample.
  • the second power device 33 provides a negative pressure to the sampling needle 31 for the second syringe, so that the sampling needle 31 sucks the blood sample in the test tube until the blood sample flows into the erythrocyte sedimentation rate detection tube 11.
  • the driving device drives the sampling needle 31 to move above the routine blood reaction tank 21, and the second syringe 33 provides positive pressure to the sampling needle 31 to drip a part of the blood sample in the sampling needle 31 into the routine blood reaction tank 21 through the needle 311 In order to detect blood routine parameters.
  • the second power device 33 provides negative pressure to the sampling needle 31, and sucks a part of the blood sample remaining in the sampling needle 31 into the ESR detection pipeline 11 to perform the red blood cell sedimentation rate detection.
  • the sampling needle 31 distributes blood to the routine blood reaction pool 21, it can be ensured that there is still a blood sample in the erythrocyte sedimentation detection tube 11 for the erythrocyte sedimentation detection module for detection, so that it is not necessary to use the second power device to remove the remaining blood in the sampling needle 31 A part of the blood sample is drawn into the erythrocyte sedimentation rate detection tube 11.
  • the first power plant 14 and the second power plant 33 may also be independent power plants.
  • the first syringe and the second syringe are independent syringes, so that different syringes can be used for different scenarios.
  • the erythrocyte sedimentation rate detection usually requires a syringe with a flow rate of 100uL/S (higher flow rate requirements) in order to better realize the red blood cell depolymerization process described in detail later.
  • the sampling and separation of blood does not require a large flow rate (high accuracy requirements).
  • the flow rate of the first syringe ie, the erythrocyte sedimentation power device
  • the second syringe ie, the sampling power device
  • the blood routine detection module 20 may include a third syringe 23 connected to the blood routine reaction tank 21 through a diluent supply line 22, and the third syringe is configured to supply diluent The pipeline 22 sucks the diluent into the blood routine reaction tank 21.
  • the blood routine reaction tank 21 may include a first optical reaction tank 211 for white blood cell detection and/or a second optical reaction tank 212 for red blood cell detection (for example, reticulocyte detection), and the blood routine detection device includes an optical detection unit. twenty four.
  • the third syringe 23 is also configured to suck the blood sample to be tested in the first optical reaction cell 211 and/or the second optical reaction cell 212 into the sample preparation pipeline 27 for optical detection.
  • the second power device 33 configured as a second syringe is also configured to push the blood sample to be tested in the sample preparation pipeline 27 for optical detection to the optical detection unit 24.
  • the blood routine reaction cell 21 may also include an impedance detection reaction tank 213 for red blood cell and/or platelet detection, and the blood routine detection device includes an impedance detection unit 25.
  • the third syringe 23 is also configured to suck the blood sample to be tested in the impedance detection reaction cell into the sample preparation pipeline for impedance detection
  • the second syringe 33 is also configured to The blood sample to be tested in the sample preparation pipeline for impedance detection is pushed into the impedance detection unit 25.
  • the blood routine detection device may include a hemoglobin detection unit 26.
  • the third syringe 23 is also configured to suck the blood sample to be tested into the sample preparation tube for hemoglobin detection, and the second syringe 33 is also configured to be able to transfer the blood sample to the sample preparation tube for hemoglobin detection.
  • the blood sample to be tested in the road is pushed to the hemoglobin detection unit 26.
  • the range of the second syringe 33 is slightly upgraded. More preferably, the range of the second syringe 33 is between 100 uL and 300 uL, for example, 250 uL. Since the second syringe 33 has a larger measuring range, it is beneficial to improve the quantitative accuracy of the second syringe 33 on the one hand, and on the other hand, it is beneficial to select a motor with a smaller step as the driving motor for the second syringe 33, for example, for a 250uL second syringe 33 You can choose a motor whose step is half of the motor step used for 100uL syringes as the drive motor, which can take into account the requirements of quantitative accuracy and quantitative volume at the same time; at the same time, the motor can run at high speed to meet the high-speed suction and discharge flow of the second syringe 33 during the erythrocyte sedimentation rate test. Demand.
  • the range of the third syringe 23 is milliliter
  • the first power device 14 and the third syringe 23 configured as the first syringe may be the same syringe.
  • the second power device 33 configured as a second syringe drives the sampling needle 31 to suck the blood sample into the sampling needle 31 until the blood sample flows into the power supply line 32; Then, the sampling needle 31 first moves to the blood routine reaction pool 21 of the blood routine detection module 20 for blood separation; then, the control valves 34, 36, and 28 are switched, so that the third syringe 23 can drive the remaining blood sample in the sampling needle 31 Flow to the erythrocyte sedimentation rate detection pipeline 11; then start the ESR detection and blood routine detection at the same time or time-sharing, and ensure that the blood sample in the erythrocyte sedimentation rate detection pipeline 11 does not shift during the ESR detection; the pipeline is cleaned after the detection is completed.
  • the first power device 14, the second power device 33, and the third syringe 23 may be the same syringe, which can further reduce the cost.
  • the syringe since there is only one syringe, the syringe first drives the sampling needle 31 to aspirate the sample, and then drives the sampling needle 31 to divide blood to the blood routine detection module 20 (B); then the blood routine The detection module 20 performs routine blood measurement first, and after the routine blood measurement is completed, the remaining blood sample (A) in the sampling needle 31 is driven by the syringe to flow in the ESR detection pipeline 11 for ESR detection; when the detection is completed After that, the pipeline is cleaned.
  • the erythrocyte sedimentation rate detection module 10 further includes an erythrocyte sedimentation reaction tank 13 independent of the routine blood reaction tank 21, The erythrocyte sedimentation reaction tank 13 is connected to one end of the erythrocyte sedimentation detection pipeline 11, and the erythrocyte sedimentation reaction tank 13 is used to receive the first part of the blood sample distributed by the sampling needle 31.
  • the first power device 14, especially the first syringe, is used to drive the first part of the blood sample in the erythrocyte sedimentation reaction tank 13 to flow into the erythrocyte sedimentation rate detection tube 11, and to make the first part of the blood sample flow to the detection area in the erythrocyte sedimentation rate detection tube 11 Then stop moving and keep it still, so that the erythrocyte sedimentation rate optical detection device 12 detects the erythrocyte sedimentation rate of the first part of the blood sample.
  • an exemplary specific working process of the blood distribution of the sample analyzer provided in the present application is as follows: under the control of the control module 50
  • the driving device first drives the sampling needle 31 to move to the test tube loaded with the blood sample.
  • the second power device 33 especially the second syringe, provides negative pressure to the sampling needle 31 so that the sampling needle 31 can suck the blood sample in the test tube.
  • the driving device first drives the sampling needle 31 to move above the ESR reaction tank 13, and the second power device 33 provides positive pressure to the sampling needle 31 to drip the first part of the blood sample in the sampling needle 31 into the ESR reaction tank 13.
  • the first power device 14 especially the first syringe, draws the blood sample from the ESR reaction tank 13 into the ESR detection pipeline 11 to detect the red blood cell sedimentation rate.
  • the driving device then drives the sampling needle 31 to move above the routine blood reaction tank 21, and the second power device 33 provides positive pressure to the sampling needle 31 to drip the second part of the blood sample in the sampling needle 31 into the routine blood reaction tank 21 to detect blood routine parameters.
  • the driving device first drives the sampling needle 31 to move above the blood routine reaction tank 21, and the second power device 33 provides positive pressure to the sampling needle 31 to drip the second part of the blood sample in the sampling needle 31 into the blood routine
  • the reaction tank 21 is used to detect blood routine parameters.
  • the driving device then drives the sampling needle 31 to move above the erythrocyte sedimentation reaction tank 13, and the second power device 33 provides positive pressure to the sampling needle 31 to drip the first part of the blood sample in the sampling needle 31 into the erythrocyte sedimentation reaction tank 13.
  • the first power device 14 draws the blood sample from the ESR reaction tank 13 into the ESR detection pipeline 11 to detect the red blood cell sedimentation rate.
  • the sampling needle 31 after the sampling needle 31 distributes the blood samples to the erythrocyte sedimentation rate detection module 10 and the blood routine detection module 20, the sampling needle 31 can be cleaned in preparation for collecting the next blood sample.
  • the first power device 14 is used to drive the erythrocyte sedimentation rate back and forth.
  • the first part of the blood sample in the tube 11 is detected.
  • the first power device 14 is configured as the first syringe, since the movement speed and the movement direction of the syringe can be flexibly set, the blood sample can be flexibly disaggregated and the blood volume can be saved.
  • the number of reciprocations can be reduced to achieve the depolymerization effect.
  • control module 50 is configured to control the first power device 14, especially the first syringe, of the erythrocyte sedimentation rate detection module 10 during the detection of the erythrocyte sedimentation rate detection module 10, such that:
  • the first power device 14 drives the first part of blood samples to flow back and forth in the erythrocyte sedimentation rate detection tube 11 for a predetermined number of times; it should be noted that the predetermined number of times may be a preset value, or a processing device such as a controller may pass a preset number. Set a value calculated by the calculation method.
  • the first power device 14 stop driving immediately after driving the first part of blood sample to the detection area 113 of the erythrocyte sedimentation rate detection tube 11, so that the first part of blood sample is in the detection area 113 of the erythrocyte sedimentation rate detection tube 11 Keep it still, so that the erythrocyte sedimentation rate optical detection device 12 detects the red blood cell aggregation rate of the first part of the blood sample, that is, detects the degree of light absorption or scattering by the blood sample in the detection area, so as to obtain the red blood cell sedimentation rate.
  • the elastic deformation coefficient of the pipeline from the sampling needle 31 to the first power device 14, especially the first syringe should be designed to ensure the shear force in the pipeline when the first power device 14 performs reciprocating depolymerization. Meet the requirements. More preferably, there is no adapter in the above-mentioned pipeline, so as to eliminate the influence of the adapter on the elastic deformation.
  • control module 50 is configured to make the first power device 14 execute when the first power device 14, especially the first syringe, drives the first part of the blood sample to flow back and forth in the erythrocyte sedimentation detection tube 11 for a predetermined number of times. The following actions for the predetermined number of times:
  • the first part of the blood sample is driven at the second speed to flow in the erythrocyte sedimentation rate detection tube 11 in a second direction opposite to the first direction for a second stroke.
  • the first speed is the same as the second speed
  • the first stroke is the same as the second stroke.
  • control module 50 can also control the first power device 14, especially the first syringe, according to the blood routine parameters measured by the blood routine detection module 20.
  • control module 50 is configured to first start the blood routine detection module 20 to detect the blood routine parameters of the second part of the blood sample, and then start the blood sedimentation detection module 10 to perform the blood routine parameter detection on the first part of the blood sample after the blood routine detection module 20 ends the blood routine parameter detection. Detection of erythrocyte sedimentation rate.
  • control module 50 is further configured to adjust the first speed, the second speed, the first stroke, the second stroke, and the predetermined number of times during the detection of the erythrocyte sedimentation rate detection module 10 according to the at least one blood routine parameter measured by the blood routine detection module 20 At least one of them.
  • the blood routine detection module 10 includes a red blood cell detection unit or an impedance detection unit for detecting a hematocrit (HCT), and the at least one blood routine parameter includes the hematocrit.
  • the hematocrit value is obtained by the red blood cell detection unit of the blood routine detection module 10 and transmitted to the control module 50, and the control module 50 calculates the deaggregation speed (first speed, second speed) and stroke that need to be adjusted. (First stroke, second stroke), time and/or number of reciprocations, etc., and control the first power device 14, especially the first syringe accordingly, so as to achieve a better depolymerization effect, thereby obtaining better erythrocyte sedimentation rate results. Sex. When the hematocrit is high and the blood viscosity increases, a higher disaggregation power or disaggregation time is required to obtain good deaggregation performance.
  • the first syringe 14 drives the sampling needle 31 to suck the blood sample
  • the sampling needle 31 distributes the blood sample to the routine blood detection module 20, for example, the sampling needle 31 moves to the routine blood reaction tank under the driving of the driving device, and distributes blood into the routine blood reaction tank under the driving of the first syringe 14;
  • the first syringe 14 draws the blood sample to the ESR detection area 113;
  • the first syringe 14 draws the blood sample in the ESR detection area at a first speed according to the sample HCT and moves for a first stroke;
  • the first syringe 14 reversely pushes the blood sample to move for a second stroke at the same second speed as the first speed according to the sample HCT, and the first stroke is equal to the second stroke;
  • the first syringe 14 draws and pushes the blood sample back and forth for a specified number of times, so as to homogenize the blood and make the red blood cells as dispersed as possible;
  • the first syringe 14 is stopped quickly. For example, when a stepper motor is used, the first syringe 14 can be stopped quickly, and then the movement of the blood sample is stopped quickly. Then the red blood cells in the blood sample gather in the detection area 113, causing light transmission. Rate change
  • FIG. 12 is the light transmittance change curve of the above process, where t1 is the moment when the reciprocating inhalation and expelling depolymerization starts, and t2 is the moment when the first syringe 14 stops suddenly.
  • the first syringe 14 drives the blood sample in the erythrocyte sedimentation rate detection tube 11 to reciprocate five times.
  • the at least one blood routine parameter may also include information about whether the blood sample is a chyle blood sample.
  • the time for the erythrocyte sedimentation rate detection module 10 to detect the erythrocyte sedimentation rate of the first part of blood sample and the time for the blood routine detection module 20 to detect the blood routine parameter of the second part of blood sample overlap.
  • the erythrocyte sedimentation rate detection module and the blood routine detection module are connected in series to perform corresponding erythrocyte sedimentation rate detection and blood routine detection.
  • the sample analyzer provided in the embodiment of the present application includes an erythrocyte sedimentation rate detection module 10 that can perform independent detection.
  • the erythrocyte sedimentation rate detection module 10 can detect the erythrocyte sedimentation rate of the first part of the blood sample and the blood routine detection module 20 can detect The time of the blood routine parameters of the second part of the blood sample overlaps, so that the erythrocyte sedimentation rate detection module 10 and the blood routine detection module 20 can perform parallel detection in time, so as to shorten the total time for detecting two items.
  • the sample analyzer provided in the embodiment of the present application is also provided with a sampling distribution module 30 for collecting blood samples.
  • the sampling distribution module 30 can distribute the first part of the blood sample to the erythrocyte sedimentation rate detection line 11 of the erythrocyte sedimentation rate detection module 10 and the blood
  • the second part of the sample is allocated to the blood routine detection module 20, that is, the sampling distribution module 30 allocates different parts of the same blood sample to the blood sedimentation detection module 10 and the blood routine detection module 20 respectively, so that the blood sedimentation detection module 10 and the blood routine detection module 20 can be tested independently and in parallel, and there is no need to wait for the detection of the previous detection module before the next detection module can be detected.
  • the overall detection time is short, and the detection efficiency is high.
  • control module 50 may be configured to control the sampling distribution module 30 to first distribute a part of the blood sample to the blood routine detection module 20 as the second part of the blood sample, and then distribute 10 another part of the blood sample to the erythrocyte sedimentation rate detection module as the first part. Part of the blood sample.
  • FIG. 13 shows a working sequence diagram of a sample analyzer according to an embodiment of the present application.
  • the sampling and distribution module 30 first collects a blood sample, and then distributes the first part of the blood sample to the erythrocyte sedimentation rate detection module 10. While the sampling distribution module 30 distributes the second part of the blood sample to the routine blood test module 20, the erythrocyte sedimentation rate detection module 10 starts to detect the erythrocyte sedimentation rate of the first part of the blood sample. After the sampling distribution module 30 distributes the second part of the blood sample to the routine blood test module 20, the routine blood test module 20 starts to perform routine blood test on the second part of the blood sample.
  • FIG. 14 shows another working sequence diagram of the sample analyzer according to an embodiment of the present application.
  • the difference from FIG. 13 is that after the sampling and distribution module 30 allocates the first part of the blood sample to the erythrocyte sedimentation rate detection module 10 and the second part of the blood sample to the routine blood sedimentation detection module 20, the erythrocyte sedimentation rate detection module 10 and the blood routine detection module 20 At the same time, the corresponding erythrocyte sedimentation rate test and blood routine test were started.
  • the erythrocyte sedimentation rate detection module 10 and the routine blood detection module 20 need to be cleaned after the detection is completed to perform the next detection, so as to prevent the residue of the previous blood sample from affecting the detection result of the next blood sample.
  • the sampling distribution module 30 also needs to be cleaned to collect the next blood sample to be tested.
  • the first part of blood samples detected by the erythrocyte sedimentation rate detection module 10 can also be redistributed to the blood routine detection module 20. That is, the control module 50 is configured to control the sampling and distribution module 50 to first allocate a part of the blood sample to the erythrocyte sedimentation rate detection module 10 as the first part of the blood sample, and to give the blood after the erythrocyte sedimentation rate detection module 10 finishes detecting the erythrocyte sedimentation rate of the first part of the blood sample.
  • the conventional detection module 20 allocates another part of the blood sample as the second part of the blood sample, where the second part of the blood sample includes the first part of the blood sample.
  • the first syringe, the second syringe, and/or the third syringe described above include a stepper motor, a screw nut assembly, a cylinder, and a piston provided in the cylinder, and a liquid is contained in the cylinder.
  • the screw nut assembly is connected to the piston, and the stepping motor drives the screw nut assembly to move the piston in the cylinder.
  • the erythrocyte sedimentation rate optical detection device 12 includes a light emitter 121 and a light receiver 122.
  • the light transmitter 121 and the light receiver 122 are respectively located on both sides of the detection area of the detection pipeline 11.
  • the light emitter 121 is used to illuminate the first part of the blood sample in the detection zone.
  • the light receiver 122 is used to detect the change of the light emitted by the light emitter 121 after irradiating the first part of the blood sample (for example, receiving the light transmitted and/or scattered by the first part of the blood sample), and by detecting the amount of light received How much to detect the degree of absorption or scattering of light by the first part of the blood sample.
  • the first power device 14 drives the first part of the blood sample to flow into the detection tube 11, and stops the movement after the first part of the blood sample flows to the detection area, and then keeps the first part of the blood sample in place. move.
  • the light emitter 121 irradiates the first part of the blood sample in the detection area, and the light receiver 122 detects the degree to which the light emitted by the light emitter 121 is scattered or transmitted after irradiating the first part of the blood sample in the detection area, that is, through the detection light receiver 122 The amount of light received is used to detect the red blood cell sedimentation rate.
  • the scattering or transmission of the light irradiated on the blood sample will change. Therefore, it is possible to detect the transmission or scattering of light after the irradiated blood sample is received. To detect the degree of light scattering or absorption of the first part of the blood sample, so as to measure the red blood cell sedimentation rate.
  • the number of the optical receiver 122 is one or more, which is not limited here.
  • the detection pipeline 11 is made of a hose, and the detection area of the detection pipeline 11 is made of a light-transmitting material. Therefore, the detection pipeline 11 can be arbitrarily arranged flexibly, for example, it can be arranged vertically, horizontally, or inclinedly, or arranged in a curved manner, which is not limited.
  • the detection pipeline 11 is configured as a capillary tube.
  • the erythrocyte sedimentation rate detection tube 11 is made of FEP (Fluorinated ethylene propylene, fluorinated ethylene propylene copolymer).
  • FEP Fluorinated ethylene propylene, fluorinated ethylene propylene copolymer
  • the erythrocyte sedimentation rate detection module 10 provided by the sample analyzer provided in the present application detects the red blood cell sedimentation rate by detecting the degree of light scattering or absorption of the red blood cells in the blood sample during the aggregation process (that is, the ESR is achieved by detecting the aggregation speed of the red blood cells. Detection), compared to the detection method of waiting for the red blood cells to settle naturally under the action of gravity (Weiman's method), the detection speed is faster, the red blood cell sedimentation rate detection can be completed in a short time (for example, 20s), and the blood consumption is less. Only about 100uL.
  • the hard detection tube must be installed in a straight line and installed vertically or slightly inclined, which tends to make the instrument too large.
  • the installation angle of the detection pipeline 11 provided in the embodiment of the present application is not limited, and can be flexibly adjusted according to the settings of other structures inside the sample analyzer, so that the overall volume of the sample analyzer can be reduced, and the sample analyzer occupies a small space. .
  • the erythrocyte sedimentation rate detection module 10 may further include a temperature sensor 15 and a heater 16 arranged near the detection area 113 of the erythrocyte sedimentation rate detection pipeline 11 that are communicatively connected with the control module 50.
  • the sensor 15 is used to detect the temperature value of the blood sample in the erythrocyte sedimentation rate detection tube 11 and transmit the temperature value to the control module 50.
  • the control module 50 is configured to control the heater 16 to detect the erythrocyte sedimentation rate when the temperature value is less than a predetermined temperature. The blood sample in the tube 11 is heated.
  • the second aspect of the present application also provides a sample analysis method.
  • the sample analysis method may include the following steps:
  • Sampling distribution step S200 collecting the blood sample in the sample container 100 by the sampling distribution module 30, and distribute the first part of the blood sample to the erythrocyte sedimentation rate detection module 10 and distribute the second part of the blood sample to the blood routine detection module 20;
  • Red blood cell sedimentation rate detection step S210 The erythrocyte sedimentation rate detection module 10 irradiates the first part of the blood sample with light and detects the degree of absorption or scattering of the light by the first part of the blood sample to detect the red blood cells of the first part of the blood sample Settlement rate
  • Routine blood detection step S220 Routine blood detection module 20 performs blood routine parameter detection on the second part of the blood sample.
  • the erythrocyte sedimentation rate optical detection device 12 of the erythrocyte sedimentation rate detection module irradiates the first part of the blood sample with light and detects the degree of absorption or scattering of light by the first part of the blood sample to The erythrocyte sedimentation rate of the first part of the blood sample is detected.
  • the erythrocyte sedimentation power device immediately stops driving after driving the first part of the blood sample to the detection area 113 of the erythrocyte sedimentation rate detection tube 11, so that the blood sample The first part remains stationary in the detection area 113, so that the erythrocyte sedimentation rate optical detection device 12 detects the red blood cell aggregation rate of the first part of the blood sample, that is, detects the degree of light absorption or scattering by the blood sample in the detection area, So as to obtain the red blood cell sedimentation rate.
  • the sampling allocation step S200 includes:
  • the driving device of the sampling distribution module 30 drives the sampling needle 311 of the sampling distribution module 30 to move to the sample container 100;
  • the driving device drives the sampling needle 31 to move to the blood routine detection module 20;
  • the second power device 33 drives the sampling needle 311 through the power supply line 32 to distribute the second part of the blood sample to the blood routine testing module 20.
  • sample analysis method may be:
  • Sampling distribution step S200 the sampling needle 21 is driven by the sampling power device through the power supply line 32 to suck the blood sample in the container 100, and then the second part of the blood sample is distributed to the blood routine detection module 20;
  • Erythrocyte sedimentation rate detection step S210 After the blood sample distribution of the blood routine detection module 20 is finished, the erythrocyte sedimentation power device of the erythrocyte sedimentation rate detection module 10 draws the first part of the blood sample from the sampling needle 31 to the AND of the erythrocyte sedimentation rate detection module 10.
  • the erythrocyte sedimentation rate optical detection device 12 of the erythrocyte sedimentation rate detection module 10 irradiates the first part of the blood sample with light and detects the degree of light absorption or scattering of the first part of the blood sample , To detect the erythrocyte sedimentation rate of the blood sample; wherein the first part of the blood sample and the second part of the blood sample are different parts of the same blood sample;
  • Routine blood detection step S220 The routine blood detection module 20 performs blood routine parameter detection on the second part of the distributed blood sample.
  • the first power unit 14 and the second power unit 33 may be the same syringe.
  • the erythrocyte sedimentation rate detection line 11 is a part of the power supply line 32.
  • the sample analysis method according to the present application may include:
  • the driving device drives the sampling needle 31 to move to the sample container 100, and the first syringe 14 drives the sampling needle 31 through the power supply line 32 to suck and sample the blood sample in the container 100.
  • the driving device drives the sampling needle 31 to move above the routine blood reaction pool 21, and the first syringe 14 drives the sampling needle 31 through the power supply line 32 to distribute a part of the collected blood sample to the routine blood reaction pool 21 to Detect blood routine parameters.
  • the first syringe 14 drives the remaining blood sample in the sampling needle 31 to flow into the ESR detection pipeline 11 directly connected to one end of the sampling needle 311 to detect the red blood cell sedimentation rate.
  • S300, S310, S320, and S330 are implemented in sequence.
  • the third syringe 23 draws the diluent into the routine blood detection module 20 through the diluent supply line 22, so as to The second part of the blood sample is processed.
  • first power unit 14 and the third syringe 23 configured as the first syringe may also be the same syringe.
  • the erythrocyte sedimentation rate optical detection device 12 performs the first part of the blood sample Before the red blood cell sedimentation rate test, include:
  • the first power device 14 especially the first syringe, drives the first part of the blood sample to flow back and forth in the erythrocyte sedimentation rate detection tube 11 for a predetermined number of times;
  • the first power device 14 stop driving immediately after driving the first part of the blood sample to the detection area 113 of the erythrocyte sedimentation rate detection tube 11, so that the first part of the blood sample is in the detection area of the erythrocyte sedimentation rate detection tube 11.
  • the erythrocyte sedimentation rate optical detection device 12 detects the red blood cell aggregation rate of the first part of the blood sample, that is, detects the degree of absorption or scattering of light by the blood sample in the detection area, so as to obtain the red blood cell sedimentation rate .
  • the first power device 14, especially the first syringe, driving the first part of the blood sample to flow back and forth in the erythrocyte sedimentation rate detection tube 11 for a predetermined number of times includes repeating the following steps for the predetermined number of times:
  • the first power device 14 drives the first part of the blood sample to flow in the erythrocyte sedimentation rate detection tube 11 for a first stroke in a first direction at a first speed;
  • the first power device 14 drives the first part of the blood sample at the second speed to flow in the erythrocyte sedimentation detection tube 11 in a second direction opposite to the first direction for a second stroke.
  • the first speed is the same as the second speed
  • the first stroke is the same as the second stroke
  • the erythrocyte sedimentation rate detection process can be adjusted according to blood routine parameters.
  • the blood routine parameter detection of the blood routine detection module 20 is started first, and the erythrocyte sedimentation rate detection of the blood sedimentation detection module 10 is started after the blood routine detection module 20 ends the blood routine parameter detection.
  • the first power device 14, especially the first syringe, driving the first part of the blood sample to flow back and forth in the erythrocyte sedimentation rate detection pipeline 11 for a predetermined number of times includes: measuring according to the routine blood detection module 20 To adjust at least one of the first speed, the second speed, the first stroke, the second stroke, and the predetermined number of times. It is particularly advantageous that the at least one blood routine parameter includes hematocrit.
  • the time when the erythrocyte sedimentation rate detection module 10 starts to detect the erythrocyte sedimentation rate of the first part of the blood sample is the same or different from the time when the blood routine detection module 20 starts to detect the blood routine parameters of the second part of the blood sample.
  • the sample analysis method includes:
  • the blood routine detection module 20 firstly start the blood routine detection module 20 to detect the blood routine parameters of the second part of the blood sample, and then start the blood sedimentation detection module 10 to detect the erythrocyte sedimentation rate of the first part of the blood sample.
  • the sampling allocation step S200 includes:
  • the sampling distribution module 30 collects blood samples.
  • the sampling distribution module 30 first distributes a part of the collected blood sample to the erythrocyte sedimentation rate detection module 10, and then distributes another part of the collected blood sample to the blood routine detection module 20;
  • the sampling distribution module 30 first distributes a part of the collected blood sample to the blood routine detection module 20, and then distributes another part of the collected blood sample to the erythrocyte sedimentation rate detection module 10.
  • the sampling allocation step S200 includes:
  • the sampling distribution module 30 first collects a part of the blood sample and distributes a part of the collected blood sample to the erythrocyte sedimentation rate detection module 10 or the blood routine detection module 20.
  • the sampling and distribution module 30 collects another part of the blood sample and distributes the other part of the collected blood sample to the blood routine detection module 20 or the erythrocyte sedimentation rate detection module 10.
  • the sampling and distribution module 30 first distributes a blood sample to the blood routine detection module 20 and starts the routine blood test, and then the sampling distribution module 30 distributes the blood sample to the blood sedimentation detection module 10 and starts the red blood cell sedimentation rate detection. Since the ESR detection method used in the present application is faster than the blood routine detection speed, the blood routine detection module 20 is allocated blood samples first and the blood routine detection is started to facilitate the production of the total detection report as soon as possible.
  • the sampling allocation step S200 includes:
  • the driving device drives the sampling needle 31 to move to the sample container to collect blood samples in the sample container.
  • the driving device drives the sampling needle 31 to move to the erythrocyte sedimentation rate detection module and the blood routine detection module, respectively, to allocate the first part of the blood sample to the blood sedimentation detection module 10 and the second part of the blood sample to the blood routine detection module 20.
  • the sample analysis method includes:
  • the driving device drives the sampling needle 31 to move to the sample container to collect a blood sample in the sample container.
  • the driving device drives the sampling needle 31 to move above the erythrocyte sedimentation reaction tank 13, and the sampling needle 31 drops the first part of the blood sample into the erythrocyte sedimentation reaction tank 13.
  • the first power device 14 especially the first syringe, drives the first part of the blood sample in the ESR reaction tank 13 to flow into the ESR detection pipeline 11, and stops the movement of the first part of the blood sample after flowing to the detection area and keeps it still .
  • the erythrocyte sedimentation rate optical detection device 12 illuminates the first part of the blood sample in the erythrocyte sedimentation rate detection pipeline 11, and detects the red blood cell sedimentation rate by detecting the degree of absorption or scattering of the light by the first part of the blood sample.
  • the driving device drives the sampling needle 31 to move above the routine blood reaction tank 21, and the sampling needle 31 drops the second part of the blood sample into the routine blood reaction tank 21.
  • the blood routine detection device performs routine blood parameter detection on the second part of the blood sample in the routine blood reaction tank 21.
  • step S410 is implemented before or after step S440.
  • Steps S420 and S430 are implemented before or after step S450.
  • the sample analysis method further includes: cleaning the sampling needle 31.
  • the time for the erythrocyte sedimentation rate detection module 10 to detect the erythrocyte sedimentation rate of the first part of the blood sample and the time for the blood routine detection module 20 to detect the blood routine parameter of the second part of the blood sample overlap, so that the erythrocyte sedimentation rate detection module 10 and the blood routine testing module 20 can perform parallel testing in time to shorten the total time for testing two items.
  • the blood sample allocated to the erythrocyte sedimentation rate detection module 10 can also be reused in order to save the amount of blood used.
  • the sample analysis method includes:
  • the second power device 33 drives the sampling needle 31 through the power supply line 32 to suck and sample the blood sample in the container 100;
  • the driving device drives the sampling needle 31 to move to the blood routine detection module 30, and the second power device 33 drives the sampling needle 31 through the power supply line 32 to remove the collected blood.
  • the second part of the sample is allocated to the blood routine detection module 30, wherein the blood sample of the second part includes the blood sample of the first part;
  • the blood routine detection module 30 performs blood routine parameter detection on the second part of the collected blood sample.
  • the sample analyzer method further includes correcting the red blood cell sedimentation rate according to the result of the blood routine parameter. As a result, more accurate red blood cell sedimentation rate detection results can be obtained.
  • sample analysis method provided in the second aspect of the present application is especially applied to the above-mentioned sample analyzer provided in the first aspect of the present application.
  • the advantages and more embodiments of the sample analysis method of the present application can be referred to the above description of the sample analyzer, which will not be repeated here.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Hydrology & Water Resources (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

一种样本分析仪和样本分析方法，样本分析仪包括血沉检测模块（10）、血常规检测模块（20）和采样分配模块（30），采样分配模块（30）采集血液样本并将血液样本的第一部分分配给血沉检测模块（10）以及将血液样本的第二部分分配给血常规检测模块（20）。血沉检测模块（10）的第一注射器（14）驱动第一部分血液样本在血沉检测管路（11）中流动并使其停止在血沉检测管路（11）的检测区（113）中。血沉检测模块（10）的血沉光学检测装置（12）通过检测第一部分血液样本对光的吸收或散射程度来检测红细胞沉降率。血常规检测模块（20）对第二部分血液样本进行血常规参数检测。通过应用第一注射器（14）作为红细胞沉降率测量的动力装置，有利于实现红细胞快速解聚，在不增加血量的情况下提高红细胞沉降率的测量精度，无需使用太长的血沉检测管路（11），降低了血沉检测管路（11）的清洗难度和清洗成本。

Description

样本分析仪及样本分析方法 技术领域
本申请涉及医疗设备技术领域，具体涉及一种样本分析仪及样本分析方法。
背景技术
在体内的血液中，因为血液的流动以及红细胞表面负电荷的相互排斥，红细胞呈分散悬浮状态。而离体的血液在静置时，红细胞会因重力作用而下沉。当处于病理状态时，血浆中蛋白的种类与含量会发生变化，将改变血液中电荷的平衡，使红细胞表面负电荷减少，进而使红细胞形成缗钱状而加快沉降。因此，可以通过检测红细胞在1小时内沉降的速率，即红细胞沉降率(Erythrocyte sedimentation rate,ESR)，来辅助病症评估。
尽管ESR在诊断上的灵敏度和特异性不高，但它依然被认为是一种可靠的、间接的急性时相炎症反应因子，在临床中有着长期广泛的应用。例如，ESR广泛应用于感染性疾病、急慢性炎症、风湿病、结缔组织病、癌症及霍奇金病等病程的治疗与监控。
目前已知一些通过测量红细胞聚集指数来预测红细胞沉降率的方法，这些方法表明了红细胞聚集指数与红细胞沉降率参数间存在较好的相关性。为了测量红细胞聚集指数，首先要对红细胞进行解聚，亦即让红细胞呈现单个分散状态，然后测量单个分散的红细胞聚集到聚集状态过程中的透光率变化，进而获得聚集指数或者说红细胞沉降率(ESR)。
为了对红细胞进行解聚，Alifax公司公开了一种采用蠕动泵对红细胞进行解聚的装置，蠕动泵抽取血液进入毛细管内部。当血液在毛细管内部流动、红细胞受到剪切力作用时，红细胞的聚集状态被破坏，待红细胞分散变得均匀后，蠕动泵立即停止，红细胞会重新聚集起来，测量聚集过程中的透光率曲线来测量红细胞沉降率(ESR)。
然而，采用蠕动泵进行解聚的过程中，为了使得红细胞达到均匀化状态，血液需要流经较长毛细管，导致血液在毛细管中被稀释液稀释，降低ESR的测量精度。而如果在该情况下要提高测量精度，则需要大幅提高ESR的用血量。由于血液粘度较高，血液在毛细管中流动时会产生显著的残留损失，而血液残留损失与血液流经的毛细管的长度成正比，导致管路的清洗时间、清洗液消耗量、污染率增加，同时也导致试剂成本增加。
发明内容
因此，本申请的目的在于提供一种集成了血常规检测和血沉(红细胞沉降率ESR)检测的样本分析仪以及一种相应的样本分析方法，其能够实现红细胞快速解聚，从而实现红细胞沉降率的快速检测，并且能够在不增加血量的情况下提高红细胞沉降率的测量精度。
为了实现本申请的目的，本申请第一方面提供了一种样本分析仪，包括血沉检测模块、血常规检测模块和采样分配模块。其中，所述采样分配模块设置用于采集血液样本，并将所述血液样本的第一部分分配给所述血沉检测模块以及将所述血液样本的第二部分分配给所述血常规检测模块。所述血沉检测模块包括血沉检测管路和血沉光学检测装置，所述血沉检测管路设置用于为被分配的第一部分血液样本提供检测场所，所述血沉光学检测装置设置用于对分配至所述血沉检测管路中的第一部分血液样本进行光照射并且通过检测所述第一部分血液样本对光的吸收或散射程度来检测所述血液样本的红细胞沉降率，其中，所述血沉检测模块包括与所述血沉检测管路相连接的第一注射器，所述第一注射器设置用于驱动所述第一部分血液样本在所述血沉检 测管路中流动。所述血常规检测模块包括血常规反应池和血常规检测装置，所述血常规反应池设置用于为被分配的第二部分血液样本提供与试剂混合的场所，所述血常规检测装置设置用于对所述血常规反应池中所述第二部分血液样本与试剂混合得到的待测血液样本进行血常规参数检测。
本申请第二方面提供了一种样本分析方法，所述样本分析方法包括采样分配步骤、红细胞沉降率检测步骤和血常规检测步骤。
在采样分配步骤中，由采样分配模块采集样本容器中的血液样本，并且将所述血液样本的第一部分分配给血沉检测模块以及将所述血液样本的第二部分分配给血常规检测模块。
在红细胞沉降率检测步骤中，由所述血沉检测模块的第一注射器将所述血液样本的第一部分抽吸到所述血沉检测模块的血沉检测管路中，由所述血沉检测模块的血沉光学检测装置对所述血液样本的第一部分进行光照射并检测所述血液样本的第一部分对光的吸收或散射程度，以检测所述血液样本的第一部分的红细胞沉降率。
在血常规检测步骤中，由所述血常规检测模块对所述血液样本的第二部分的血常规参数进行检测。
在本申请提供的样本分析仪和样本分析方法中，通过应用注射器作为红细胞沉降率测量的动力装置，有利于实现红细胞快速解聚以及提高红细胞沉降率的测量速度和测量精度，而无需增加血量，也无需使用太长的血沉检测管路，进而降低了检测成本以及降低了血沉检测管路的清洗难度和清洗成本。此外，通过采用注射器还能够实现良好地兼容目前用于血常规检测的血液细胞分析仪。
附图说明
本申请上述和/或附加方面的优点和特征从结合下面附图对实施例的描述中将变得明显和容易理解，其中：
图1是本申请第一方面提供的样本分析仪的第一实施例的结构示意图；
图2是本申请第一方面提供的样本分析仪的第二实施例的结构示意图；
图3是本申请第一方面提供的样本分析仪的第三实施例的结构示意图；
图4是本申请第一方面提供的样本分析仪的第四实施例的结构示意图；
图5是图4所示的样本分析仪的一种检测时序图；
图6是本申请第一方面提供的样本分析仪的一种液路结构示意图；
图7是本申请第一方面提供的样本分析仪的第五实施例的结构示意图；
图8是图7所示的样本分析仪的一种检测时序图；
图9是本申请第一方面提供的样本分析仪的第六实施例的结构示意图；
图10是图9所示的样本分析仪的一种检测时序图；
图11是本申请第一方面提供的样本分析仪的第七实施例的结构示意图；
图12是本申请第一方面提供的样本分析仪的一种血沉检测过程的吸光度曲线图；
图13和图14是本申请第一方面提供的样本分析仪的不同检测时序图；
图15至图17是本申请第二方面提供的样本分析方法的不同实施例的示意流程图。
具体实施方式
为使本申请实施例的目的、技术方案和优点更加清楚，下面将结合本申请实施例中的附图，对本申请实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本申请的一部分实施例，而不是全部的实施例。基于本申请中的实施例，本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例，都属于本申请保护的范围。
请参考图1，本申请第一方面提供一种样本分析仪，包括血沉检测模块10、血常 规检测模块20和采样分配模块30。
采样分配模块30用于采集血液样本，并将血液样本的第一部分(即第一部分血液样本)分配给血沉检测模块10的血沉检测管路11以及将血液样本的第二部分(即第二部分血液样本)分配给血常规检测模块20。此时，采样分配模块可以配置为先后分配血液样本的第一部分和第二部分，也可以配置为同时分配血液样本的第一部分和第二部分，对分配次序不做限定。
在一些实施例中，采样分配模块30可以通过采用一次采集、分两次分配的方式或者通过分两次采集并分配的方式实现将血液样本的第一部分分配给血沉检测模块10的血沉检测管路11以及将血液样本的第二部分分配给血常规检测模块20的血常规反应池21。
具体地，一次采集、分两次分配的方式为：采样分配模块30采集血液样本后，采样分配模块30先将所采集的血液样本的一部分(即第一部分血液样本)分配给血沉检测模块10的血沉检测管路11、再将所采集的血液样本的另一部分(即第二部分血液样本)分配给血常规检测模块20的血常规反应池21，或采样分配模块30先将所采集的血液样本的一部分(即第二部分血液样本)分配给血常规检测模块20的血常规反应池21、再将所采集的血液样本的另一部分(即第一部分血液样本)分配给血沉检测模块10的血沉检测管路11。
分两次采集并分配的方式为：采样分配模块30先采集血液样本的一部分并将采集到的血液样本的一部分分配给血沉检测模块10的血沉检测管路11或血常规检测模块20的血常规反应池21；采样分配模块30再采集血液样本的另一部分并将采集到的血液样本的另一部分分配给血常规检测模块20的血常规反应池21或血沉检测模块10的血沉检测管路11。
血沉检测模块10包括血沉检测管路11和血沉光学检测装置12，血沉检测管路11用于为被分配的第一部分血液样本提供检测场所，血沉光学检测装置12用于对分配至血沉检测管路11中的第一部分血液样本进行光照射并且检测分配至血沉检测管路11中的第一部分血液样本对光的吸收或散射程度来检测血液样本的红细胞沉降率。在血沉光学检测装置12进行红细胞沉降率检测时，第一部分血液样本在血沉检测管路11中不发生位移，即保持静止不动。
血常规检测模块20包括血常规反应池21和血常规检测装置(图1未示出)，血常规反应池21用于为被分配的第二部分血液样本提供与试剂混合的场所，所述血常规检测装置对血常规反应池21中第二部分血液样本与试剂混合得到的待测血液样本进行血常规检测。
本领域技术人员能够理解，血常规检测装置可以为光学检测单元、阻抗检测单元和血红蛋白检测单元中的至少一个。相应地，血常规反应池可以包括光学反应池、阻抗检测反应池和血红蛋白检测反应池中的至少一个。在血常规检测模块20对血液样本进行血常规检测时，可以将血液样本和相应的试剂(例如稀释液和/或溶血剂和/或染色剂等等)加入到血常规反应池21中，由血常规检测装置对血常规反应池21中的血液样本进行测量，以获得至少一种血常规参数，血常规参数可以包括WBC(White blood cell，白细胞)五分类结果、WBC计数和形态参数、HGB(Hemoglobin，血红蛋白)的功能测量、RBC(Red blood cell，红细胞)以及PLT(blood platelet，血小板)计数和形态参数中的至少一种或多种组合，在实际血常规检测过程中，可以根据需要增加或减少血常规检测项目，在此不做限定。
本申请实施例提供的样本分析仪设置有血沉检测模块10和血常规检测模块20，血沉检测模块10能够通过血沉检测管路11和血沉光学检测装置12检测血液的红细胞沉降率，血常规检测模块20能够检测血常规参数，进而使得本申请提供的样本分析仪既能够检测红细胞沉降率，又能够检测血常规，在临床实际应用中，一台设备即可 实现两个血液检测项目，功能多样，使用更加方便。
在一些实施例中，请参考图2，样本分析仪还包括液路支持模块40，用于为釆样分配模块30、血沉检测模块10和血常规检测模块20提供液路支持。具体地，液路支持模块40通过给采样分配模块30、血沉检测模块10和血常规检测模块20提供液体来进行液路支持。例如，液路支持模块40可以分别给采样分配模块30、血沉检测模块10和血常规检测模块20提供清洗液，以分别对采样针31、血沉检测管路11和血常规反应池21进行清洗，避免污染待检测的血液样本、导致检测结果不准确。例如，血沉检测模块和血常规检测模块的试剂加样、反应混匀、测量动作、清洗维护等均由液路支持模块辅助完成。
此外，样本分析仪还包括控制模块50，控制模块50分别与采样分配模块30、血沉检测模块10、血常规检测模块20和液路支持模块40相连接，控制模块50用于分别控制采样分配模块30、血沉检测模块10、血常规检测模块20和液路支持模块40的动作，以使采样分配模块30、血沉检测模块10、血常规检测模块20和液路支持模块40之间相互配合、完成对红细胞沉降率和血常规参数的检测。
在此，控制模块50可以包括处理器和存储器。处理器可以为CPU，GPU或其它具有运算能力的芯片。存储器中装有操作系统和应用程序等供处理器执行的各种计算机程序及执行该计算机程序所需的数据。
如图1所示，血沉检测模块10还包括与血沉检测管路11、在此与其第一端111相连接的第一动力装置(也可以称为血沉动力装置)14，第一动力装置14设置用于驱动第一部分血液样本在血沉检测管路11中流动并使第一部分血液样本流动到血沉检测管路11内的检测区113后停止运动并保持不动，以便血沉光学检测装置12对第一部分血液样本的红细胞沉降率进行检测。也就是说，第一动力装置14不仅用于将第一部分血液样本驱动到血沉检测管路11中，还用于保证在进行红细胞沉降率检测时使得血沉检测管路11中的血液样本保持不动。
在一个具体的示例中，本申请实施例提供的检测ESR的工作过程如下：第一动力装置14驱动第一部分血液样本流动到血沉检测管路11中，当第一部分血液样本流动到血沉检测管路11的特定位置(检测区113)后，第一动力装置14突然停止并瞬时中断血沉检测管路11中第一部分血液样本的流动，从而导致第一部分血液样本在此时突然发生减速(或停止流动)，随后发生红细胞的聚集和沉淀。在红细胞发生聚集和沉淀的过程中，将导致血沉光学检测装置12检测到的信号的变化，从而获得用于确定ESR的信息。也就是说，控制模块50配置用于在控制第一动力装置14将第一部分血液样本驱动到血沉检测管路11的检测区113后立即停止第一动力装置14的驱动，从而使所述第一部分血液样本在检测区113中保持不动，以便血沉光学检测装置12对所述第一部分血液样本的红细胞聚集速率进行检测、即检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
相对于现有技术中的魏氏法，本申请实施例提供的样本分析仪可以限制血沉检测管路11的长度，不仅可以减少整个仪器的体积，还可以减少检测分析所需要的血液量、清洗血沉检测管路11的清洗液的用量，进而大大降低了集成ESR检测和血常规检测的样本分析仪的成本。
在一些实施例中，第一动力装置14还可以在检测完红细胞沉降率后驱动第一部分血液样本在血沉检测管路11内流动以排出血沉检测管路11，为下一次检测做准备。
第一动力装置14可以为泵或注射器或其他能提供动力的压力源。
如在背景技术中所描述的，采用蠕动泵作为血沉检测模块的液体动力源将导致大幅增加用血量。此外，由于此时需要较长的检测管路，导致血样在检测管路流动时的残留量增加，这不仅导致血样浪费，也增加了检测管路的清洗难度以及清洗量，进而也增加了交叉污染的可能性。而且，蠕动泵传输液体的液量可大可小，精度差，适合 于液体定量低要求的场合，但无法适用于血球测量领域的高精度定量(数微升级)分样要求。另外，在集成了血常规检测和ESR检测的一体机中，采用蠕动泵作为血沉检测模块的液体动力源将将会导致在采样分配模块中需要设置两个动力源，即，一个用于驱动采样部吸取和排放样本，另一个蠕动泵作为血沉检测模块的液体动力源，这在布置蠕动泵与采样分配模块时存在技术上的困难，因为蠕动泵与采样分配模块难以共同存在血液分析仪中，而且会极大地提高了一体机的成本、体积和构造复杂度。
因此特别有利的是，如图3所示，第一动力装置14构造为第一注射器。该构造方案不仅有利于快速且精确地检测ESR(由于注射器的精确定量作用，能够将血液样本精确地抽吸到血沉检测管路11的检测区113中)，而且有利于将血沉检测模块10简单且低成本地集成到现有的血常规分析仪中，而且基本上不增加或很少增加血常规分析仪的体积。
在一些实施例中，请参考图1和图3，采样分配模块30可以包括采样针31和驱动装置(图未示出)。驱动装置用于驱动采样针31运动，以便采样针31釆集血液样本并将血液样本的一部分分配给血常规检测模块20的血常规反应池21。
如图3所示，血液样本通常储存于试管100中，并且试管100的顶端设有用于密封的盖子。驱动装置驱动采样针31移动到对应试管100的上方，并驱动采样针31以其针尖或针头311的一端刺破试管的盖子，然后伸入到试管中，吸取试管内的血液样本，以采集血液样本。
在一些实施例中，如图3所示，采样分配模块30还可以包括通过动力供应管路32与采样针31的远离针头311的一端312连接的第二动力装置(也可以称为采样动力装置)33(也就是说，动力供应管路32设置用于采样针31的远离针头311的一端312与第二动力装置33连接)，第二动力装置33用于通过所述动力管路31驱动所述采样针31通过针头311抽吸或排放血液样本。进一步地，第二动力装置33用于通过动力供应管路32为采样针提供负压以吸取血液样本以及提供正压以排放血液样本。第二动力装置33可以为泵或注射器或其他能提供动力的压力源、例如正负气压源。在此特别有利的是，第二动力装置33构造为第二注射器。
在一些实施例中，如图3和4所示，第一动力装置14和第二动力装置33可以为同一动力装置，尤其是第一注射器和第二注射器为同一注射器。由于用于血常规的定量分血的第二注射器通常精度要求比较高，将第二注射器同时用作第一注射器不仅能够实现ESR的快速且精确额检测，而且能够进一步降低样本分析的成本。
在一些实施例中，如图1、3和4所示，血沉检测管路11的与第一端111相对置的第二端112可以与采样针31的远离针头311的一端312连接。此时优选地，样本分析仪的血液分配的一个示例性的具体工作过程可以为：控制模块50控制第二动力装置33驱动采样针31通过针头311将第二部分血液样本分配到血常规反应池21，然后控制第一动力装置14将第一部分血液样本从采样针31的远离针头311的一端312抽吸到血沉检测管路11中，其中，第一部分血液样本与第二部分血液样本为同一血液样本的不同部分。在Alifax公司的专利CN1864060B中公开的串联地集成ESR模块和细胞计数模块的方法中，由于ESR模块与细胞计数模块串联布置于一条血样回路上，在测量时，由采样模块采集的样本沿血样回路流动，首先经过ESR模块进行ESR测量，然后经过细胞计数模块进行血常规测量。但在该方案中血样必须首先流经ESR模块，后续再经过血常规模块，使得要进行血常规检测的血样流经了较多的稀释液区域，导到血样受到稀释及污染，从而导致血常规检测不准确。因此，通过先后给血常规检测模块20和血沉检测模块10分配同一血液样本的完全不同的部分，能够实现在集成了血常规检测和血沉检测的情况下降低对用于血常规检测的血段的污染，从而提高血常规检测的准确性，此外有利于实现血常规检测模块20和血沉检测模块10的并行检测。
优选地，在图3和4所示的实施例中，动力供应管路32的一部分可以为血沉检测管路11。例如，将动力供应管路32靠近采样针31的部分设置为血沉检测管路11。此时，第二动力装置33优选用作第一动力装置14并进一步用于将采样针31中的血液样本的一部分(即为第一部分血液样本A)抽吸至血沉检测管路11中。而采样针31仍然通过针头311将采样针31中的一部分血液样本(即第二部分血液样本B)分配到血常规反应池21，以进行血常规参数检测。也就是说，在该实施例中，第二动力装置33、尤其是第二注射器被复用为第一动力装置14、尤其是第一注射器且采样针31的动力供应管路32被复用为血沉检测管路11，不用另外设置反应池和动力装置，因此结构简单，而且降低了成本。在此可以理解的，第二注射器33通过控制阀34分别与动力供应管路32以及稀释液存储部35连接。当控制阀34将第二注射器33与稀释液存储部35连通时，第二注射器33从稀释液存储部35抽取稀释液；当控制阀34将第二注射器33与动力供应管路32连通时，第二注射器33通过动力供应管路32来为采样针31提供抽吸动力或排放动力。
也就是说，血沉检测管路11在结构上可以直接与采样针31后端管路、即动力供应管路直接耦合，由此能够实现在不增加仪器复杂程度以及尽可能改动小的情况下简单地将血沉检测模块10集成到现有的血液分析仪中。如图5所示的工作时序图，第二动力装置33(尤其是第二注射器)或者说第一动力装置14(尤其是第一注射器)驱动采样针31将血液样本抽吸至采样针31内直至血液样本流动至血沉检测管路11中。然后，采样针31例如首先运动至血常规检测模块20的血常规反应池21进行分血(血段B)，分血完成后需要保证血沉检测管路11内仍然还有血液样本(血段A)，或者保证采样针31内仍然还有血液样本(血段A)能够被抽吸至血沉检测管路11。然后同时或分时启动ESR检测与血常规检测，并且保证ESR检测时，血沉检测管路11内的血样不发生位移。当检测完成后进行管路清洗。。
图4所示的样本分析仪的血液分配的一个示例性的具体工作过程如下：在控制模块50的控制下
驱动装置首先驱动采样针31移动至装载有血液样本的试管100处。
第二动力装置33、在此为第二注射器给采样针31提供负压，以便采样针31吸取试管中的血液样本，直至血液样本流动至血沉检测管路11内。
驱动装置驱动采样针31移动到血常规反应池21的上方，第二注射器33给采样针31提供正压，以将采样针31中的血液样本的一部分通过针头311滴入到血常规反应池21内，以检测血常规参数。
接着，第二动力装置33给采样针31提供负压，将采样针31内剩余的血液样本的一部分抽吸到血沉检测管路11内，以进行红细胞沉降率检测。或者也可以在采样针31给血常规反应池21分血之后，保证血沉检测管路11内仍然存在血液样本供血沉检测模块进行检测，从而不必再通过第二动力装置将采样针31内剩余的血液样本的一部分抽吸到血沉检测管路11内。
当然，在备选的实施例中，第一动力装置14和第二动力装置33也可以为彼此独立的动力装置。特别是，第一注射器和第二注射器为彼此独立的注射器，由此能够针对不同的场景采用不同的注射器。血沉检测通常需要流量为100uL/S级别的注射器(对流速要求较高)，以便更好地实现后面还要详细描述的红细胞解聚过程。而采样分血则不需要大流量(对精确度要求较高)，就此而言，第一注射器(即血沉动力装置)的流速可以大于第二注射器(即采样动力装置)的流速。
在一些实施例中，如图6所示，血常规检测模块20可以包括通过稀释液供应管路22与血常规反应池21连接的第三注射器23，该第三注射器设置用于通过稀释液供应管路22将稀释液抽吸到血常规反应池21中。
例如，血常规反应池21可以包括用于白细胞检测的第一光学反应池211和/或用 于红细胞检测(例如网织红细胞检测)的第二光学反应池212，血常规检测装置包括光学检测单元24。第三注射器23还设置为能将在第一光学反应池211和/或第二光学反应池212中的待测血液样本抽吸到用于光学检测的样本准备管路27中。构造为第二注射器的第二动力装置33还设置为能将在用于光学检测的样本准备管路27中的待测血液样本推送到光学检测单元24中。
此外，进一步参见图6，血常规反应池21还可以包括用于红细胞和/或血小板检测的阻抗检测反应池213，所述血常规检测装置包括阻抗检测单元25。此时，第三注射器23还设置为能将阻抗检测反应池中的待测血液样本抽吸到用于阻抗检测的样本准备管路中，第二注射器33还设置为能将在所述用于阻抗检测的样本准备管路中的待测血液样本推送到阻抗检测单元25中。备选地或附加地，血常规检测装置可以包括血红蛋白检测单元26。此时，第三注射器23还设置为能将待测血液样本抽吸到用于血红蛋白检测的样本准备管路中，第二注射器33还设置为能将在所述用于血红蛋白检测的样本准备管路中的待测血液样本推送到血红蛋白检测单元26中。
优选地，第二注射器33的量程为微升级。更为优选地，第二注射器33的量程在100uL～300uL之间，例如为250uL。由于第二注射器33的量程较大，一方面利于提升第二注射器33的定量精度，另一方面利于针对第二注射器33选择步距更小的电机作为驱动电机，例如，对于250uL的第二注射器33可选择步距为用于100uL注射器的电机步距一半的电机作为驱动电机，这样可同时兼顾定量精度和定量体积的要求；同时电机能高速运行，满足血沉测试时第二注射器33高速吸排流量的需求。优选地，第三注射器23的量程为毫升级，例如为10mL。
本领域技术人员可以理解的，第二注射器33和第三注射器23的上述各个功能可以通过阀控制技术来实现。
在一些实施例中，如图7所示，构造为第一注射器的第一动力装置14和第三注射器23可以为同一注射器。此时，如图8的工作时序图所示，构造为第二注射器的第二动力装置33驱动采样针31将血液样本抽吸至采样针31内直至血液样本流动至动力供应管路32中；然后，采样针31例如首先运动至血常规检测模块20的血常规反应池21进行分血；接着通过切换控制阀34、36和28，使得第三注射器23能够驱动采样针31中剩余的血液样本流动至血沉检测管路11中；然后同时或分时启动ESR检测与血常规检测，并且保证ESR检测时，血沉检测管路11内的血样不发生位移；当检测完成后进行管路清洗。在图7所示的实施例中，第三注射器23通过控制阀28与稀释液存储部29和光学检测单元24连接。
在另一实施例中，如图9所示，第一动力装置14、第二动力装置33和第三注射器23可以为同一注射器，由此能够进一步减少成本。此时，如图10的工作时序图所示，由于仅具有一个注射器，因此该注射器先驱动采样针31吸样，然后驱动采样针31给血常规检测模块20分血(B)；接着血常规检测模块20先进行血常规测量，待血常规测量完成后再由该仅一个的注射器驱动采样针31中剩余的血液样本(A)在血沉检测管路11内流动以进行ESR检测；当检测完成后进行管路清洗。
在一些备选的实施例中，请参考图11，不同于血沉检测管路11直接与采样针31连接的实施例，血沉检测模块10还包括独立于血常规反应池21的血沉反应池13，血沉反应池13与血沉检测管路11的一端相连接，血沉反应池13用于接收采样针31分配的第一部分血液样本。第一动力装置14、尤其是第一注射器用于驱动血沉反应池13中的第一部分血液样本流动到血沉检测管路11中，并使第一部分血液样本流动到血沉检测管路11内的检测区后停止运动并保持不动，以便血沉光学检测装置12对第一部分血液样本的红细胞沉降率进行检测。
在图11所示的实施例中，本申请提供的样本分析仪的血液分配的一个示例性具体工作过程如下：在控制模块50的控制下
驱动装置首先驱动采样针31移动至装载有血液样本的试管处。
第二动力装置33、尤其是第二注射器给采样针31提供负压，以便采样针31吸取试管中的血液样本。
然后，驱动装置先驱动采样针31移动到血沉反应池13的上方，第二动力装置33给采样针31提供正压，以将采样针31中的血液样本的第一部分滴入到血沉反应池13内。接着，第一动力装置14、尤其是第一注射器将血沉反应池13的血液样本抽吸到血沉检测管路11内，以检测红细胞沉降率。驱动装置再驱动采样针31移动到血常规反应池21的上方，第二动力装置33给采样针31提供正压，以将采样针31中的血液样本的第二部分滴入到血常规反应池21内，以检测血常规参数。
或者，驱动装置先驱动采样针31移动到血常规反应池21的上方，第二动力装置33给采样针31提供正压，以将采样针31中的血液样本的第二部分滴入到血常规反应池21内，以检测血常规参数。驱动装置再驱动采样针31移动到血沉反应池13的上方，第二动力装置33给采样针31提供正压，以将采样针31中的血液样本的第一部分滴入到血沉反应池13内。接着，第一动力装置14将血沉反应池13的血液样本抽吸到血沉检测管路11内，以检测红细胞沉降率。
在本实施例中，采样针31将血液样本分别分配给血沉检测模块10和血常规检测模块20后，即可清洗采样针31，以为采集下一份血液样本做准备。
为了在血沉光学检测装置12检测红细胞沉降率之前使得血沉检测管路11的第一部分血液样本中的红细胞尽可能处于分散状态，以便更加准确地测量红细胞沉降率，采用第一动力装置14往复驱动血沉检测管路11的第一部分血液样本。特别是在第一动力装置14构造为第一注射器的情况下，由于可灵活地设定注射器的运动速度以及运动方向，能够灵活地对血样进行解聚，而且能够节约血量。特别是在使用大流量高速注射器的情况下，可以减少往复次数，以达到解聚效果。
因此，在一些实施例中，控制模块50配置为在血沉检测模块10的检测期间控制血沉检测模块10的第一动力装置14、尤其是第一注射器，使得：
第一动力装置14驱动所述第一部分血液样本在血沉检测管路11中来回流动预定次数；应当说明的是，预定次数可以是预先设定的一个数值，也可以是控制器等处理装置通过预设的计算方式计算得出的一个数值。
然后使第一动力装置14在将所述第一部分血液样本驱动到血沉检测管路11的检测区113后立即停止驱动，从而使所述第一部分血液样本在血沉检测管路11的检测区113中保持不动，以便血沉光学检测装置12对第一部分血液样本的红细胞聚集速率进行检测、即检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
优选地，从采样针31到第一动力装置14、尤其是第一注射器之间的管路的弹性形变系数应设计成保证在第一动力装置14执行往复解聚时管路内的剪切力达到要求。更优选地，上述管路中也没有转接头，以消除转接头对弹性形变的影响。
在一个具体的实施例中，控制模块50配置为在控制第一动力装置14、尤其是第一注射器驱动第一部分血液样本在血沉检测管路11中来回流动预定次数时使第一动力装置14执行所述预定次数的下列动作：
以第一速度驱动第一部分血液样本在血沉检测管路11中沿第一方向流动第一行程；
然后，以第二速度驱动第一部分血液样本在血沉检测管路11中沿反向于第一方向的第二方向流动第二行程。
优选地，第一速度与第二速度相同，第一行程与第二行程相同。由此能够实现第一动力装置14、尤其是第一注射器的简单控制。
进一步地，控制模块50还可以根据血常规检测模块20测得的血常规参数来控制 第一动力装置14、尤其是第一注射器。此时，控制模块50配置为先启动血常规检测模块20对第二部分血液样本的血常规参数检测，在血常规检测模块20结束血常规参数检测后再启动血沉检测模块10对第一部分血液样本的红细胞沉降率检测。然后，控制模块50进一步配置为在血沉检测模块10的检测期间根据血常规检测模块20测得的至少一个血常规参数来调整第一速度、第二速度、第一行程、第二行程以及预定次数中的至少一个。
优选地，血常规检测模块10包括用于检测红细胞压积(HCT)的红细胞检测单元或阻抗检测单元，所述至少一个血常规参数包括所述红细胞压积。也就是说，由血常规检测模块10的红细胞检测单元获得红细胞比容值并将其传输给控制模块50，控制模块50计算出需要调整的解聚速度(第一速度、第二速度)、行程(第一行程、第二行程)、时间和/或往复次数等并据此控制第一动力装置14、尤其是第一注射器，以便性能更优的解聚效果，进而获得更好的血沉结果一致性。当红细胞压积高时，血液黏度升高，则需要采用更高的解聚动力或者解聚时间，以获得良好的解聚性能。
在第一注射器14和第二注射器33为同一注射器并且血沉检测管路11为动力供应管路32的一部分的情况下，采用往复吸吐解聚的一种示例性流程如下：在控制模块50的控制下
第一注射器14驱动采样针31吸取血样；
采样针31分配血样给血常规检测模块20，例如采样针31在驱动装置的驱动下运动到血常规反应池上，在第一注射器14的驱动下向血常规反应池中分血；
第一注射器14抽拉血样至ESR检测区113；
第一注射器14根据样本HCT以第一速度在ESR检测区抽拉血样运动第一行程；
第一注射器14根据样本HCT以与第一速度相同的第二速度反向推动血样运动第二行程，第一行程等于第二行程；
第一注射器14来回抽拉和推动血样指定次数，以使血液均匀化并使得红细胞尽可能呈分散状态；
第一注射器14迅速停止，例如在采用步进电机驱动的情况下可以急速地停止第一注射器14，进而急速地停止血样的运动，然后血样中的红细胞在检测区113内发生聚集，引起透光率变化；
对第一注射器14急停后的曲线作积分，与ESR值对应，建立关联关系，最后报告红细胞沉降率值。
图12为上述过程的透光率变化曲线，其中，t1为开始往复吸吐解聚的时刻，t2为第一注射器14的急停时刻。在此，第一注射器14驱动血沉检测管路11中的血液样本往复运动5次。
当然，所述至少一个血常规参数也可以包括关于血液样本是否为乳糜血样本的信息。
在一些实施例中，血沉检测模块10检测第一部分血液样本的红细胞沉降率的时间与血常规检测模块20检测第二部分血液样本的血常规参数的时间有交叠。
与现有技术中将血沉检测模块和血常规检测模块串联起来先后进行相应的红细胞沉降率检测和血常规检测不同，本申请实施例提供的样本分析仪包括可分别独立进行检测的血沉检测模块10和血常规检测模块20，无需等待上一检测模块检测结束后才能进行下一检测模块的检测，进而可以使血沉检测模块10检测第一部分血液样本的红细胞沉降率的时间与血常规检测模块20检测第二部分血液样本的血常规参数的时间有交叠，从而使得血沉检测模块10和血常规检测模块20在时间上可以进行并行检测，以缩短检测两个项目的总时长。
而且本申请实施例提供的样本分析仪还设置了用于采集血液样本的采样分配模块30，采样分配模块30可以将血液样本的第一部分分配给血沉检测模块10的血沉检 测管路11以及将血液样本的第二部分分配给血常规检测模块20，即采样分配模块30给血沉检测模块10和血常规检测模块20分别分配同一份血液样本的不同部分，进而使得血沉检测模块10和血常规检测模块20之间可分别独立并行检测，无需等待上一检测模块检测结束后才能进行下一检测模块的检测，总体检测时间短，从而检测效率高。例如，控制模块50可以配置为控制采样分配模块30先给血常规检测模块20分配所述血液样本的一部分作为第二部分血液样本，再给血沉检测模块分配10所述血液样本的另一部分作为第一部分血液样本。
请参考图13，图13示出本申请一实施例的样本分析仪的工作时序图。采样分配模块30首先采集血液样本，然后将血液样本的第一部分分配给血沉检测模块10。在采样分配模块30将血液样本的第二部分分配给血常规检测模块20的同时，血沉检测模块10开始对血液样本的第一部分进行红细胞沉降率检测。在采样分配模块30将血液样本的第二部分分配给血常规检测模块20之后，血常规检测模块20开始对血液样本的第二部分进行血常规检测。
请参考图14，图14示出本申请一实施例的样本分析仪的另一工作时序图。与图13不同的是，在采样分配模块30将血液样本的第一部分分配给血沉检测模块10以及将血液样本的第二部分分配给血常规检测模块20之后，血沉检测模块10和血常规检测模块20同时开始相应的红细胞沉降率检测和血常规检测。
此外，血沉检测模块10和血常规检测模块20在检测结束后，均需要进行清洗，以进行下一次检测，避免上一份待测血液样本的残留影响下一份待测血液样本的检测结果。采样分配模块30也需要清洗，以采集下一份待测血液样本。
当然，在备选的实施例中，为了进一步节省血液样本，也可以将经血沉检测模块10检测的第一部分血液样本重新分配给血常规检测模块20。即，控制模块50配置为控制采样分配模块50先给血沉检测模块10分配血液样本的一部分作为第一部分血液样本，并且在血沉检测模块10结束对第一部分血液样本的红细胞沉降率检测之后再给血常规检测模块20分配血液样本的另一部分作为第二部分血液样本，其中，第二部分血液样本包括第一部分血液样本。
在一些实施例中，上述第一注射器、第二注射器和/或第三注射器包括步进电机、丝杆螺母组件、缸体和设置在该缸体中的活塞，在所述缸体中容纳液体，所述丝杆螺母组件与所述活塞相连，所述步进电机通过驱动所述丝杆螺母组件来使所述活塞在所述缸体中运动。
在一些实施例中，请参考图1、3和图11，血沉光学检测装置12包括光发射器121和光接收器122。光发射器121和光接收器122分别位于检测管路11的检测区的两侧。光发射器121用于照射检测区内的血液样本的第一部分。光接收器122用于检测光发射器121发射的光经照射第一部分血液样本后的变化量(例如接收被第一部分血液样本透射的光和/或散射的光)，通过检测接收到的光的多少来检测第一部分血液样本对光的吸收或散射程度。
在启动血沉检测模块10进行检测时，第一动力装置14驱动第一部分血液样本流动到检测管路11内，并使第一部分血液样本流动到检测区后停止运动，然后使第一部分血液样本保持不动。光发射器121照射检测区内的第一部分血液样本，光接收器122检测光发射器121发射的光经照射检测区内的第一部分血液样本后散射或透射的程度，即，通过检测光接收器122接收到的光的量来检测红细胞沉降率。
由于血液样本中的红细胞在聚集(形成缗钱状)的过程中，照射在血液样本上的光的散射或透射会发生变化，因此，就能够通过检测接收经照射血液样本后透射或散射光的量来检测第一部分血液样本对光散射或吸收的程度，从而测出红细胞沉降率。
光接收器122的数量为一个或多个，在此不做限定。
在本申请一实施例中，检测管路11由软管制成，检测管路11的检测区由透光材 料制成。因此，检测管路11可以任意灵活设置，例如可以竖直、水平或倾斜设置，也可以弯曲设置，此不做限定。
在本申请一实施例中，检测管路11构成为毛细管。
在本申请一实施例中，血沉检测管路11由FEP(Fluorinated ethylene propylene，氟乙烯丙烯共聚物)制成。当血沉检测管路11为动力供应管路32的一部分时，动力供应管路由FEP制成。
由于本申请提供的样本分析仪设置的血沉检测模块10是通过检测血液样本中的红细胞在聚集的过程中对光的散射或吸收程度来检测红细胞沉降率的(即通过检测红细胞聚集速度来实现ESR检测)，相对于等待红细胞根据重力作用自然沉降的检测方式(魏氏法)，检测速度更快，能够在很短的时间(例如20s)内完成红细胞沉降率检测，而且耗血量更少，只有约100uL。此外，对于魏氏法而言，必须使硬质检测管直线设置并且竖直或稍微倾斜设置，由此容易使得仪器体积过大。而本申请实施例提供的检测管路11的设置角度不受限制，能够根据样本分析仪内部其他结构的设置做出灵活调整，从而能够减小样本分析仪的整体体积，样本分析仪占用空间小。
此外，在一些实施例中，如图2所示，血沉检测模块10还可以包括与控制模块50通信连接的设置在血沉检测管路11的检测区113附近的温度传感器15和加热器16，温度传感器15用于检测血沉检测管路11中的血液样本的温度值并将该温度值传输给控制模块50，控制模块50配置用于当所述温度值小于预定温度时控制加热器16对血沉检测管路11中的血液样本进行加热。
本申请第二方面还提供一种样本分析方法，如图15所示，所述样本分析方法可以包括下列步骤：
采样分配步骤S200：由采样分配模块30采集样本容器100中的血液样本，并且将血液样本的第一部分分配给血沉检测模块10以及将血液样本的第二部分分配给血常规检测模块20；
红细胞沉降率检测步骤S210：血沉检测模块10对所述血液样本的第一部分进行光照射并检测所述血液样本的第一部分对光的吸收或散射程度，以检测所述血液样本的第一部分的红细胞沉降率；
血常规检测步骤S220：血常规检测模块20对所述血液样本的第二部分进行血常规参数检测。
优选地，在红细胞沉降率检测步骤S210中，由血沉检测模块10的第一动力装置(也可以称为血沉动力装置)14、尤其是第一注射器将所述血液样本的第一部分抽吸到血沉检测模块10的血沉检测管路11中，由血沉检测模块的血沉光学检测装置12对所述血液样本的第一部分进行光照射并检测所述血液样本的第一部分对光的吸收或散射程度，以检测所述血液样本的第一部分的红细胞沉降率。
在一些实施例中，在红细胞沉降率检测步骤S210中，血沉动力装置在将所述血液样本的第一部分驱动到血沉检测管路11的检测区113后立即停止驱动，从而使所述血液样本的第一部分在检测区中113保持不动，以便血沉光学检测装置12对所述血液样本的第一部分的红细胞聚集速率进行检测、即检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
在一些实施例中，采样分配步骤S200包括：
由采样分配模块30的驱动装置驱动采样分配模块30的采样针311运动至样本容器100；
由采样分配模块30的第二动力装置(也可以称为采样动力装置)33、尤其是第二注射器通过动力供应管路32驱动采样针311吸取样本容器100中的血液样本；
由所述驱动装置驱动采样针31运动至血常规检测模块20；
由第二动力装置33通过动力供应管路32驱动采样针311将所述血液样本的第二 部分分配给血常规检测模块20。
备选地，所述样本分析方法可以为：
采样分配步骤S200：由采样动力装置通过动力供应管路32驱动采样针21吸取样本容器100中的血液样本，然后将所述血液样本的第二部分分配给血常规检测模块20；
红细胞沉降率检测步骤S210：在血常规检测模块20的血液样本分配结束后，由血沉检测模块10的血沉动力装置将所述血液样本的第一部分从采样针31抽吸到血沉检测模块10的与采样针31连接的血沉检测管路11中，由血沉检测模块10的血沉光学检测装置12对所述血液样本的第一部分进行光照射并检测所述血液样本的第一部分对光的吸收或散射程度，以检测所述血液样本的红细胞沉降率；其中，所述血液样本的第一部分与所述血液样本的第二部分为同一血液样本的不同部分；
血常规检测步骤S220：由血常规检测模块20对被分配的所述血液样本的第二部分进行血常规参数检测。
在一些实施例中，第一动力装置14和第二动力装置33可以为同一注射器。在此，特别优选的是，血沉检测管路11为动力供应管路32的一部分。此时，如图16所示，按照本申请的样本分析方法可以包括：
S300，驱动装置驱动采样针31运动至样本容器100，由第一注射器14通过动力供应管路32驱动采样针31吸取样本容器100中的血液样本。
S310，驱动装置驱动采样针31移动到血常规反应池21的上方，由第一注射器14通过动力供应管路32驱动采样针31将所采集的血液样本的一部分分配给血常规反应池21，以检测血常规参数。
S320，第一注射器14驱动采样针31内剩余的血液样本流动到与采样针311的一端直接连接的血沉检测管路11内，以检测红细胞沉降率。
S330，在检测完红细胞沉降率后，清洗采样针31。
在该实施例中，S300、S310、S320以及S330按顺序先后实施。
在一些实施例中，在血常规检测步骤S220中，在对血常规参数进行检测之前，由第三注射器23通过稀释液供应管路22将稀释液抽吸到血常规检测模块20中，以便对所述血液样本的第二部分进行处理。
在此，构造为第一注射器的第一动力装置14与第三注射器23也可以为同一注射器。
在一些实施例中，在红细胞沉降率检测步骤S210中，在将所述血液样本的第一部分抽吸到血沉检测管路11中之后并在血沉光学检测装置12对所述血液样本的第一部分进行红细胞沉降率检测之前，包括：
第一动力装置14、尤其是第一注射器驱动所述血液样本的第一部分在血沉检测管路11中来回流动预定次数；
然后使第一动力装置14在将所述血液样本的第一部分驱动到血沉检测管路11的检测区113后立即停止驱动，从而使所述血液样本的第一部分在血沉检测管路11的检测区113中保持不动，以便血沉光学检测装置12对所述血液样本的第一部分的红细胞聚集速率进行检测、即检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
进一步地，第一动力装置14、尤其是第一注射器驱动所述血液样本的第一部分在血沉检测管路11中来回流动预定次数包括重复所述预定次数的下列步骤：
第一动力装置14以第一速度驱动所述血液样本的第一部分在血沉检测管路11中沿第一方向流动第一行程；
然后，第一动力装置14以第二速度驱动所述血液样本的第一部分在血沉检测管路11中沿反向于第一方向的第二方向流动第二行程。
优选地，所述第一速度与所述第二速度相同，所述第一行程与所述第二行程相同。
进一步地还可以根据血常规参数来调整血沉检测过程。此时，先启动血常规检测模块20的血常规参数检测，在血常规检测模块20结束血常规参数检测后再启动血沉检测模块10的红细胞沉降率检测。在红细胞沉降率检测步骤S210过程中，第一动力装置14、尤其是第一注射器驱动所述血液样本的第一部分在血沉检测管路11中来回流动预定次数包括：根据血常规检测模块20测得的至少一个血常规参数来调整所述第一速度、所述第二速度、所述第一行程、所述第二行程以及所述预定次数中的至少一个。特别有利的是，所述至少一个血常规参数包括红细胞压积。
在一些实施例中，血沉检测模块10启动检测血液样本的第一部分的红细胞沉降率的时间与血常规检测模块20启动检测第二部分血液样本的血常规参数的时间相同或不相同。
在一些实施例中，所述样本分析方法包括：
先启动血沉检测模块10对血液样本的第一部分的红细胞沉降率的检测，后启动血常规检测模块20对血液样本的第二部分的血常规参数的检测；
或先启动血常规检测模块20对血液样本的第二部分的血常规参数的检测，后启动血沉检测模块10对血液样本的第一部分的红细胞沉降率的检测。
在一些实施例中，采样分配步骤S200包括：
采样分配模块30采集血液样本。
采样分配模块30先将所采集的血液样本的一部分分配给血沉检测模块10、再将所采集的血液样本的另一部分分配给血常规检测模块20；
或采样分配模块30先将所采集的血液样本的一部分分配给血常规检测模块20、再将所采集的血液样本的另一部分分配给血沉检测模块10。
在一些实施例中，采样分配步骤S200包括：
采样分配模块30先采集血液样本的一部分并将采集到的血液样本的一部分分配给血沉检测模块10或血常规检测模块20。
采样分配模块30再采集血液样本的另一部分并采集到的血液样本的另一部分分配给血常规检测模块20或血沉检测模块10。
优选地，采样分配模块30先给血常规检测模块20分配血液样本并启动血常规检测，然后采样分配模块30再给血沉检测模块10分配血液样本并启动红细胞沉降率检测。由于本申请所使用的ESR检测方法速度快于血常规检测速度，因此先给血常规检测模块20分配血液样本并启动血常规检测有利于尽快出总检测报告。
在一些实施例中，采样分配步骤S200包括：
驱动装置驱动采样针31运动至样本容器，以采集样本容器中的血液样本。
驱动装置驱动采样针31分别运动至血沉检测模块和血常规检测模块，以将血液样本的第一部分分配给血沉检测模块10以及将血液样本的第二部分分配给血常规检测模块20。
在一些备选的实施例中，请参考图17，样本分析方法包括：
S400，驱动装置驱动采样针31运动至样本容器，以采集样本容器中的血液样本。
S410，驱动装置驱动采样针31移动到血沉反应池13的上方，采样针31将第一部分血液样本滴入到血沉反应池13内。
S420，第一动力装置14、尤其是第一注射器驱动血沉反应池13内的第一部分血液样本流入到血沉检测管路11内，并使第一部分血液样本流动到检测区后停止运动并保持不动。
S430，血沉光学检测装置12对血沉检测管路11内的第一部分血液样本进行光照，并通过检测第一部分血液样本对光的吸收或散射程度来检测红细胞沉降率。
S440，驱动装置驱动采样针31移动到血常规反应池21的上方，采样针31将第二部分血液样本滴入到血常规反应池21内。
S450，血常规检测装置对血常规反应池21内的第二部分血液样本进行血常规参数检测。
在本申请实施例中，步骤S410在步骤S440之前或之后实施。步骤S420和S430在步骤S450之前或之后实施。
进一步地，在步骤S410和步骤S440之后，样本分析方法还包括：清洗采样针31。
在一些实施例中，血沉检测模块10检测血液样本的第一部分的红细胞沉降率的时间与血常规检测模块20检测血液样本的第二部分的血常规参数的时间有交叠，从而使得血沉检测模块10和血常规检测模块20在时间上可以进行并行检测，以缩短检测两个项目的总时长。此时，通过采样分配模块30将同一份血液样本的不同部分(即血液样本的第一部分与血液样本的第二部分完全不同)分配给血沉检测模块10和血常规检测模块20，使得血沉检测模块10和血常规检测模块20之间可分别独立并行检测，无需等上一检测模块检测结束后才能进行下一检测模块的检测，总体检测时间短，从而提高了检测效率。
在一些备选的实施例中，也可以为了节省用血量而重复利用分配给血沉检测模块10的血液样本，此时，所述样本分析方法包括：
由第二动力装置33、尤其是第二注射器通过动力供应管路32驱动采样针31吸取样本容器100中的血液样本；
由第一动力装置14、尤其是第一注射器将所采集的血液样本的第一部分抽吸到血沉检测管路11中，并由血沉光学检测装置12检测所采集的血液样本的第一部分的红细胞沉降率；
在血沉光学检测装置12结束红细胞沉降率检测后，由驱动装置驱动采样针31运动至血常规检测模块30，并由第二动力装置33通过动力供应管路32驱动采样针31将所采集的血液样本的第二部分分配给血常规检测模块30，其中，所述第二部分的血液样本包括所述第一部分的血液样本；
由血常规检测模块30对所采集的血液样本的第二部分进行血常规参数检测。
进一步地，所述样本分析仪方法还包括根据所述血常规参数的结果来修正所述红细胞沉降率。由此能够获得更加准确的红细胞沉降率检测结果。
本申请第二方面提供的样本分析方法尤其是应用于上述本申请第一方面提供的样本分析仪。本申请的样本分析方法的优点和更多实施例可参考上述对样本分析仪的描述，在此不再赘述。
需要说明的是，在本文中，诸如“第一”和“第二”等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来，而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且，术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含，从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素，而且还包括没有明确列出的其他要素，或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下，由语句“包括一个……”限定的要素，并不排除在包括要素的过程、方法、物品或者设备中还存在另外的相同要素。
以上在说明书、附图以及权利要求中所提及的特征，只要在本申请内是有意义的，均可任意相互组合。针对按照本申请的样本分析仪所描述的特征和优点以相应的方式适用于按照本申请的样本分析方法，反之亦然。
以上仅是本申请的具体实施方式，使本领域技术人员能够理解或实现本申请。对这些实施例的多种修改对本领域的技术人员来说将是显而易见的，本文中所定义的一般原理可以在不脱离本申请的精神或范围的情况下，在其它实施例中实现。因此，本申请将不会被限制于本文所示的这些实施例，而是要符合与本文所申请的原理和新颖特点相一致的最宽的范围。

Claims (36)

  1. 一种样本分析仪，其特征在于，包括血沉检测模块、血常规检测模块和采样分配模块；
    所述采样分配模块设置用于采集血液样本，并将所述血液样本的第一部分分配给所述血沉检测模块以及将所述血液样本的第二部分分配给所述血常规检测模块；
    所述血沉检测模块包括血沉检测管路和血沉光学检测装置，所述血沉检测管路设置用于为被分配的第一部分血液样本提供检测场所，所述血沉光学检测装置设置用于对分配至所述血沉检测管路中的第一部分血液样本进行光照射，且所述血沉光学检测装置通过检测所述第一部分血液样本对光的吸收或散射程度来检测所述血液样本的红细胞沉降率，其中，所述血沉检测模块包括与所述血沉检测管路相连接的第一注射器，所述第一注射器设置用于驱动所述第一部分血液样本在所述血沉检测管路中流动；
    所述血常规检测模块包括血常规反应池和血常规检测装置，所述血常规反应池设置用于为被分配的第二部分血液样本提供与试剂混合的场所，所述血常规检测装置设置用于对所述血常规反应池中所述第二部分血液样本与试剂混合得到的待测血液样本进行血常规参数检测。
  2. 根据权利要求1所述的样本分析仪，其特征在于，所述采样分配模块包括采样针和驱动装置，所述驱动装置设置用于驱动所述采样针运动。
  3. 根据权利要求2所述的样本分析仪，其特征在于，所述采样分配模块包括通过动力供应管路与所述采样针的远离针头的一端连接的第二注射器，所述第二注射器设置用于通过所述动力管路驱动所述采样针抽吸或排放所述血液样本。
  4. 根据权利要求3所述的样本分析仪，其特征在于，所述第一注射器和所述第二注射器为同一注射器。
  5. 根据权利要求4所述的样本分析仪，其特征在于，所述血沉检测管路为所述动力供应管路的一部分，所述第二注射器设置为能将所述采样针中的血液样本的一部分作为所述第一部分血液样本抽吸至所述血沉检测管路中。
  6. 根据权利要求3至5中任一项所述的样本分析仪，其特征在于，所述血常规检测模块包括通过稀释液供应管路与所述血常规反应池连接的第三注射器，该第三注射器设置用于通过所述稀释液供应管路将稀释液抽吸到所述血常规反应池中。
  7. 根据权利要求6所述的样本分析仪，其特征在于，所述血常规反应池包括用于白细胞检测的第一光学反应池和/或用于红细胞检测的第二光学反应池，所述血常规检测装置包括光学检测单元；
    所述第三注射器还设置为能将在所述第一光学反应池和/或所述第二光学反应池中的待测血液样本抽吸到用于光学检测的样本准备管路中；
    所述第二注射器还设置为能将在所述用于光学检测的样本准备管路中的待测血液样本推送到所述光学检测单元中。
  8. 根据权利要求6或7所述的样本分析仪，其特征在于，所述血常规反应池包括用于红细胞检测和/或血小板的阻抗检测反应池，所述血常规检测装置包括阻抗检测单元；
    所述第三注射器还设置为能将在所述阻抗检测反应池中的待测血液样本抽吸到用于阻抗检测的样本准备管路中；
    所述第二注射器还设置为能将在所述用于阻抗检测的样本准备管路中的待测血 液样本推送到所述阻抗检测单元中。
  9. 根据权利要求6至8中任一项所述的样本分析仪，其特征在于，所述第一注射器和所述第三注射器为同一注射器。
  10. 根据权利要求1至3中任一项所述的样本分析仪，其特征在于，所述血沉检测模块还包括独立于所述血常规反应池的血沉反应池，所述血沉反应池与所述血沉检测管路相连接，所述血沉反应池用于接收所述采样针分配的所述第一部分血液样本，所述第一注射器用于驱动所述血沉反应池中的所述第一部分血液样本流动到所述血沉检测管路中，以便所述血沉光学检测装置对所述第一部分血液样本进行红细胞沉降率检测。
  11. 根据权利要求1至10中任一项所述的样本分析仪，其特征在于，所述样本分析仪还包括与所述血沉检测模块、所述血常规检测模块和所述采样分配模块控制连接的控制模块。
  12. 根据权利要求11所述的样本分析仪，其特征在于，所述控制模块配置为在所述血沉检测模块的检测期间控制所述血沉检测模块的第一注射器，使得：
    所述第一注射器驱动所述第一部分血液样本在所述血沉检测管路中来回流动预定次数；
    然后使所述第一注射器在将所述第一部分血液样本驱动到所述血沉检测管路的检测区后立即停止驱动，从而使所述第一部分血液样本在所述血沉检测管路的检测区中保持不动，以便所述血沉光学检测装置检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
  13. 根据权利要求12所述的样本分析仪，其特征在于，所述控制模块配置为在控制所述第一注射器驱动所述第一部分血液样本在所述血沉检测管路中来回流动预定次数时使所述第一注射器执行所述预定次数的下列动作：
    以第一速度驱动所述第一部分血液样本在所述血沉检测管路中沿第一方向流动第一行程；
    然后，以第二速度驱动所述第一部分血液样本在所述血沉检测管路中沿反向于第一方向的第二方向流动第二行程。
  14. 根据权利要求13所述的样本分析仪，其特征在于，所述第一速度与所述第二速度相同，所述第一行程与所述第二行程相同。
  15. 根据权利要求13或14所述的样本分析仪，其特征在于，所述控制模块配置为先启动所述血常规检测模块对所述第二部分血液样本的血常规参数检测，在所述血常规检测模块结束血常规参数检测后再启动所述血沉检测模块对所述第一部分血液样本的红细胞沉降率检测；
    所述控制模块进一步配置为在所述血沉检测模块的检测期间根据所述血常规检测模块测得的至少一个血常规参数来调整所述第一速度、所述第二速度、所述第一行程、所述第二行程以及所述预定次数中的至少一个。
  16. 根据权利要求15所述的样本分析仪，其特征在于，所述血常规检测模块包括用于检测红细胞压积的红细胞检测单元，所述至少一个血常规参数包括所述红细胞压积。
  17. 根据权利要求11至16中任一项所述的样本分析仪，其特征在于，所述控制模块配置为控制所述采样分配模块先给所述血常规检测模块分配所述血液样本的一部分作为所述第二部分血液样本，再给所述血沉检测模块分配所述血液样本的另一部 分作为所述第一部分血液样本。
  18. 根据权利要求11至16中任一项所述的样本分析仪，其特征在于，所述控制模块配置为控制所述采样分配模块先给所述血沉检测模块分配所述血液样本的一部分作为所述第一部分血液样本，并且在所述血沉检测模块结束对所述第一部分血液样本的红细胞沉降率检测之后再给所述血常规检测模块分配所述血液样本的另一部分作为所述第二部分血液样本，其中，所述第二部分血液样本包括所述第一部分血液样本。
  19. 根据权利要求1至18中任一项所述的样本分析仪，其特征在于，所述第一注射器和/或所述第二注射器和/或所述第三注射器包括步进电机、丝杆螺母组件、缸体和设置在该缸体中的活塞，在所述缸体中容纳液体，所述丝杆螺母组件与所述活塞相连，所述步进电机通过驱动所述丝杆螺母组件来使所述活塞在所述缸体中运动。
  20. 根据权利要求1至19中任一项所述的样本分析仪，其特征在于，所述血沉检测模块检测所述第一部分血液样本的红细胞沉降率的时间与所述血常规检测模块检测所述第二部分血液样本的血常规参数的时间有交叠。
  21. 一种样本分析方法，其特征在于，所述样本分析方法包括：
    采样分配步骤：由采样分配模块采集样本容器中的血液样本，并且将所述血液样本的第一部分分配给血沉检测模块以及将所述血液样本的第二部分分配给血常规检测模块；
    红细胞沉降率检测步骤：由所述血沉检测模块的第一注射器将所述血液样本的第一部分抽吸到所述血沉检测模块的血沉检测管路中，由所述血沉检测模块的血沉光学检测装置对所述血液样本的第一部分进行光照射并检测所述血液样本的第一部分对光的吸收或散射程度，以检测所述血液样本的第一部分的红细胞沉降率；
    血常规检测步骤：由所述血常规检测模块对所述血液样本的第二部分进行血常规参数检测。
  22. 根据权利要求21所述的样本分析方法，其特征在于，所述采样分配步骤包括：
    由所述采样分配模块的驱动装置驱动所述采样分配模块的采样针运动至所述样本容器；
    由所述采样分配模块的第二注射器通过动力供应管路驱动所述采样针吸取所述样本容器中的血液样本；
    由所述驱动装置驱动所述采样针运动至所述血常规检测模块；
    由所述第二注射器通过所述动力供应管路驱动所述采样针将所述血液样本的第二部分分配给所述血常规检测模块。
  23. 根据权利要求22所述的样本分析方法，其特征在于，所述第一注射器和所述第二注射器为同一注射器。
  24. 根据权利要求22或23所述的样本分析方法，其特征在于，在所述血常规检测步骤中，在对血常规参数进行检测之前，由第三注射器通过稀释液供应管路将稀释液抽吸到所述血常规检测模块中，以便对所述血液样本的第二部分进行处理。
  25. 根据权利要求24所述的样本分析方法，其特征在于，所述第一注射器和所述第三注射器为同一注射器。
  26. 根据权利要求22至25中任一项所述的样本分析方法，其特征在于，在所述红细胞沉降率检测步骤中，在将所述血液样本的第一部分抽吸到所述血沉检测管路中之后并在所述血沉光学检测装置对所述血液样本的第一部分进行红细胞沉降率检测 之前，包括：
    所述第一注射器驱动所述血液样本的第一部分在所述血沉检测管路中来回流动预定次数；
    然后使所述第一注射器在将所述血液样本的第一部分驱动到所述血沉检测管路的检测区后立即停止驱动，从而使所述血液样本的第一部分在所述血沉检测管路的检测区中保持不动，以便所述血沉光学检测装置检测所述检测区中的血液样本对光的吸收或散射程度，从而获得红细胞沉降率。
  27. 根据权利要求26所述的样本分析方法，其特征在于，所述第一注射器驱动所述血液样本的第一部分在所述血沉检测管路中来回流动预定次数包括重复所述预定次数的下列步骤：
    所述第一注射器以第一速度驱动所述血液样本的第一部分在所述血沉检测管路中沿第一方向流动第一行程；
    然后，所述第一注射器以第二速度驱动所述血液样本的第一部分在所述血沉检测管路中沿反向于第一方向的第二方向流动第二行程。
  28. 根据权利要求27所述的样本分析方法，其特征在于，所述第一速度与所述第二速度相同，所述第一行程与所述第二行程相同。
  29. 根据权利要求28所述的样本分析方法，其特征在于，先启动所述血常规检测模块的血常规参数检测，在所述血常规检测模块结束血常规参数检测后再启动所述血沉检测模块的红细胞沉降率检测；
    所述第一注射器驱动所述血液样本的第一部分在所述血沉检测管路中来回流动预定次数包括：根据所述血常规检测模块测得的至少一个血常规参数来调整所述第一速度、所述第二速度、所述第一行程、所述第二行程以及所述预定次数中的至少一个。
  30. 根据权利要求29所述的样本分析方法，其特征在于，所述至少一个血常规参数包括红细胞压积。
  31. 根据权利要求22至30中任一项所述的样本分析方法，其特征在于，在所述采样分配步骤中，所述采样分配模块采集所述血液样本，然后先将所采集的血液样本的一部分分配给所述血常规检测模块、再将所采集的血液样本的另一部分分配给所述血沉检测模块。
  32. 根据权利要求22至30中任一项所述的样本分析方法，其特征在于，在所述采样分配步骤中：
    所述采样分配模块先采集所述血液样本的一部分并将所采集的所述血液样本的一部分分配给所述血常规检测模块；
    所述采样分配模块再采集所述血液样本的另一部分并将所采集的所述血液样本的另一部分分配给所述血沉检测模块。
  33. 根据权利要求22至30中任一项所述的样本分析方法，其特征在于，所述样本分析方法包括：
    由所述第二注射器通过所述动力供应管路驱动所述采样针吸取所述样本容器中的血液样本；
    由所述第一注射器将所采集的血液样本的第一部分抽吸到所述血沉检测管路中，并由所述血沉光学检测装置检测所采集的血液样本的第一部分的红细胞沉降率；
    在所述血沉光学检测装置结束红细胞沉降率检测后，由所述驱动装置驱动所述采样针运动至所述血常规检测模块，并由所述第二注射器通过所述动力供应管路驱动所述采样针将所采集的血液样本的第二部分分配给所述血常规检测模块，其中，所述第 二部分的血液样本包括所述第一部分的血液样本；
    由所述血常规检测模块对所采集的血液样本的第二部分进行血常规参数检测。
  34. 根据权利要求21至32中任一项所述的样本分析方法，其特征在于，所述血沉检测模块检测所述血液样本的第一部分的红细胞沉降率的时间与所述血常规检测模块检测所述血液样本的第二部分的血常规参数的时间有交叠。
  35. 根据权利要求21至34中任一项所述的样本分析方法，其特征在于，所述样本分析仪方法还包括：
    根据所述血常规参数的结果来修正所述红细胞沉降率。
  36. 根据权利要求21至35中任一项所述的样本分析方法，其特征在于，所述样本分析方法应用于根据权利要求1至20中任一项所述的样本分析仪。
PCT/CN2020/119424 2019-11-18 2020-09-30 样本分析仪及样本分析方法 WO2021098394A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080070395.6A CN114556081A (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/119181 WO2021097610A1 (zh) 2019-11-18 2019-11-18 样本分析仪及样本分析方法
CNPCT/CN2019/119181 2019-11-18

Publications (1)

Publication Number Publication Date
WO2021098394A1 true WO2021098394A1 (zh) 2021-05-27

Family

ID=72536612

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/CN2019/119181 WO2021097610A1 (zh) 2019-11-18 2019-11-18 样本分析仪及样本分析方法
PCT/CN2020/119424 WO2021098394A1 (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法
PCT/CN2020/119668 WO2021098398A1 (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法
PCT/CN2020/119436 WO2021098396A1 (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/119181 WO2021097610A1 (zh) 2019-11-18 2019-11-18 样本分析仪及样本分析方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/119668 WO2021098398A1 (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法
PCT/CN2020/119436 WO2021098396A1 (zh) 2019-11-18 2020-09-30 样本分析仪及样本分析方法

Country Status (3)

Country Link
EP (1) EP4063825A4 (zh)
CN (4) CN111712703B (zh)
WO (4) WO2021097610A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097610A1 (zh) * 2019-11-18 2021-05-27 深圳迈瑞生物医疗电子股份有限公司 样本分析仪及样本分析方法
CN114441390A (zh) * 2020-10-30 2022-05-06 深圳市瑞图生物技术有限公司 一种并发时序控制方法及精子质量分析仪、存储介质
CN116183452A (zh) * 2021-11-25 2023-05-30 深圳迈瑞生物医疗电子股份有限公司 血沉测量系统、设备、方法和计算机可读存储介质
CN116818618A (zh) * 2022-03-21 2023-09-29 深圳迈瑞生物医疗电子股份有限公司 血液样本分析仪及其控制方法
FR3134626A1 (fr) 2022-04-15 2023-10-20 Horiba Abx Sas Dispositif et méthode de numération de formule sanguine et de détermination de vitesse de sédimentation
FR3134627A1 (fr) * 2022-04-15 2023-10-20 Horiba Abx Sas Dispositif d'étalement ou coloration et de détermination de vitesse de sédimentation
FR3134625A1 (fr) * 2022-04-15 2023-10-20 Horiba Abx Sas Dispositif et méthode de détermination de vitesse de sédimentation
CN118050290A (zh) * 2022-11-16 2024-05-17 深圳迈瑞生物医疗电子股份有限公司 血沉检测装置以及血沉检测方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059208A1 (en) * 1999-11-08 2004-03-25 Sire Analytical Systems Srl. Method to determine the speed of sedimentation of blood and other parameters correlated thereto, and relative apparatus
WO2007128684A1 (en) * 2006-04-28 2007-11-15 Alifax Spa Method to detect states of anemia present in a blood sample
CN101228426A (zh) * 2005-07-13 2008-07-23 阿里法克斯国际股份公司 用于分析与血液密度相关的诸如红细胞沉降率和/或红血球聚集率的血液参数的仪器校准方法
CN104833813A (zh) * 2015-05-12 2015-08-12 江苏英诺华医疗技术有限公司 一种同时具有血液常规和生化检测功能的分析仪
CN205317792U (zh) * 2015-12-08 2016-06-15 重庆南方数控设备有限责任公司 一种自动精确化检测的魏氏法血沉仪
CN109932519A (zh) * 2019-04-19 2019-06-25 深圳市理邦精密仪器股份有限公司 血液检测装置
CN110251116A (zh) * 2019-07-15 2019-09-20 河北医科大学第一医院 一种血管通路流量检测仪及其计算方法
CN111712703A (zh) * 2019-11-18 2020-09-25 深圳迈瑞生物医疗电子股份有限公司 样本分析仪及样本分析方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2942466A1 (de) * 1979-10-20 1981-04-30 Ernst Leitz Wetzlar Gmbh, 6330 Wetzlar Verfahren zur bestimmung eines einer blutsenkung entsprechenden messwertes
US4848900A (en) * 1987-06-22 1989-07-18 Kuo Cheng Deng Computerized automatic monitoring and recording system of erythrocyte sedimentation process
JP2579788Y2 (ja) * 1992-04-02 1998-08-27 テルモ株式会社 血沈測定器具
CN2123074U (zh) * 1992-04-03 1992-11-25 天津中医学院 激光细胞聚集测定仪
JPH064668U (ja) * 1992-06-22 1994-01-21 テルモ株式会社 血沈測定台
JPH0622959U (ja) * 1992-06-22 1994-03-25 テルモ株式会社 血沈測定器具用吸引具および血沈測定器具
US5891734A (en) * 1994-08-01 1999-04-06 Abbott Laboratories Method for performing automated analysis
US6296450B1 (en) * 1999-09-03 2001-10-02 Baxter International Inc. Systems and methods for control of pumps employing gravimetric sensing
WO2001023864A1 (en) * 1999-09-27 2001-04-05 Adelio Missaglia Apparatus for testing blood samples
US6716633B2 (en) * 2000-09-18 2004-04-06 Sysmex Corporation Blood cell detector, blood analyzer and blood analyzing method using the detector
US6813949B2 (en) * 2001-03-21 2004-11-09 Mirant Corporation Pipeline inspection system
US7207939B2 (en) * 2002-10-03 2007-04-24 Coulter International Corp. Apparatus and method for analyzing a liquid in a capillary tube of a hematology instrument
ITUD20030174A1 (it) * 2003-09-03 2005-03-04 Sire Analytical Systems Srl Apparato integrato per analisi ematologiche e relativo metodo.
ITFI20030273A1 (it) * 2003-10-28 2005-04-29 Diesse Diagnostica Senese S P A Metodo e dispositivo per eseguire analisi sulla velocita'
JP4761109B2 (ja) * 2005-01-26 2011-08-31 学校法人日本大学 核の検査装置及び方法
US7481978B2 (en) * 2005-03-23 2009-01-27 Beckman Coulter, Inc. Apparatus for aspirating liquids from sealed containers
US7661326B2 (en) * 2006-10-26 2010-02-16 Beckman Coulter, Inc. Apparatus for aspirating and dispensing liquids in an automated analyzer
CN201303943Y (zh) * 2008-10-15 2009-09-09 深圳市普康电子有限公司 血细胞分析仪采样针血样分配装置
TR201001281A2 (tr) * 2010-02-22 2010-07-21 Ker�M Ba�Kurt O�Uz Tek kullanımlık kapiller tüplerde eritrosit agregasyonu ölçümü.
CN102539792B (zh) * 2010-12-31 2014-08-13 深圳迈瑞生物医疗电子股份有限公司 一种血样吸取检测方法及血样吸取检测判断系统
US9279800B2 (en) * 2012-01-13 2016-03-08 Alcor Scientific, Inc. Apparatus, method, system for the determination of the aggregation rate of red blood cells
CN110187089B (zh) * 2012-07-18 2021-10-29 赛拉诺斯知识产权有限责任公司 快速测量小容量样本中有形血液成分的沉降率
US9733175B2 (en) * 2013-06-19 2017-08-15 Shenzhen Yhlo Biotech Co., Ltd. Full-automatic erythrocyte sedimentation rate analysis meter and detecting method thereof
CN104297497B (zh) * 2013-07-16 2016-02-24 成都深迈瑞医疗电子技术研究院有限公司 血液分析方法、控制装置和血液细胞分析仪
CN104297108B (zh) * 2013-07-16 2017-09-05 成都深迈瑞医疗电子技术研究院有限公司 粒子分析仪及其液路系统
JP6360696B2 (ja) * 2014-03-18 2018-07-18 日本光電工業株式会社 血液検査装置および血液検査方法
WO2016000216A1 (zh) * 2014-07-01 2016-01-07 深圳迈瑞生物医疗电子股份有限公司 一种全血样本检测方法及血液检测仪
CN104181319A (zh) * 2014-09-11 2014-12-03 长春星锐智能化科技有限公司 一种用于全自动化学分析仪的镉柱还原检测装置
CN104458519B (zh) * 2014-12-08 2017-01-18 重庆南方数控设备有限责任公司 获取血沉数据的精确检测方法
CN104713816B (zh) * 2015-02-04 2017-06-23 深圳市帝迈生物技术有限公司 一种全血crp检测装置与方法、及一种血液细胞分析仪
JP2019506619A (ja) * 2015-12-18 2019-03-07 アボット ラボラトリーズ 自動化分析のためのシステムおよび方法
CN106248579A (zh) * 2016-08-31 2016-12-21 马东阁 一种oled血液检测设备
JP7037324B2 (ja) * 2017-01-27 2022-03-16 日本光電工業株式会社 炎症マーカー測定方法、炎症マーカー測定装置、炎症マーカー測定プログラム、および当該プログラムを記録した記録媒体
CN108732338A (zh) * 2017-04-17 2018-11-02 深圳市帝迈生物技术有限公司 一种可兼容白细胞五分类和白细胞三分群的血细胞分析仪及测试方法
CN107884563A (zh) * 2017-11-26 2018-04-06 张延艳 一种用于血液分析的医疗装置及其使用方法
CN109991430A (zh) * 2017-12-30 2019-07-09 深圳迈瑞生物医疗电子股份有限公司 样本分析仪及样本分析方法
CN208091861U (zh) * 2018-04-20 2018-11-13 重庆南方数控设备有限责任公司 一种血沉检测装置
CN208621631U (zh) * 2018-04-25 2019-03-19 深圳迈瑞生物医疗电子股份有限公司 一种样本分析系统
CN109932520A (zh) * 2019-04-19 2019-06-25 深圳市理邦精密仪器股份有限公司 血液检测装置
CN109991433B (zh) * 2019-05-05 2024-04-16 北京众驰伟业科技发展有限公司 一种血沉测试仪及血沉测试方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059208A1 (en) * 1999-11-08 2004-03-25 Sire Analytical Systems Srl. Method to determine the speed of sedimentation of blood and other parameters correlated thereto, and relative apparatus
CN101228426A (zh) * 2005-07-13 2008-07-23 阿里法克斯国际股份公司 用于分析与血液密度相关的诸如红细胞沉降率和/或红血球聚集率的血液参数的仪器校准方法
WO2007128684A1 (en) * 2006-04-28 2007-11-15 Alifax Spa Method to detect states of anemia present in a blood sample
CN104833813A (zh) * 2015-05-12 2015-08-12 江苏英诺华医疗技术有限公司 一种同时具有血液常规和生化检测功能的分析仪
CN205317792U (zh) * 2015-12-08 2016-06-15 重庆南方数控设备有限责任公司 一种自动精确化检测的魏氏法血沉仪
CN109932519A (zh) * 2019-04-19 2019-06-25 深圳市理邦精密仪器股份有限公司 血液检测装置
CN110251116A (zh) * 2019-07-15 2019-09-20 河北医科大学第一医院 一种血管通路流量检测仪及其计算方法
CN111712703A (zh) * 2019-11-18 2020-09-25 深圳迈瑞生物医疗电子股份有限公司 样本分析仪及样本分析方法

Also Published As

Publication number Publication date
CN114556082B (zh) 2024-07-19
CN114556081A (zh) 2022-05-27
CN114585901A (zh) 2022-06-03
EP4063825A1 (en) 2022-09-28
CN114556082A (zh) 2022-05-27
WO2021098398A1 (zh) 2021-05-27
WO2021098396A1 (zh) 2021-05-27
CN114585901B (zh) 2024-08-06
CN111712703A (zh) 2020-09-25
CN111712703B (zh) 2024-04-12
EP4063825A4 (en) 2023-01-25
WO2021097610A1 (zh) 2021-05-27

Similar Documents

Publication Publication Date Title
WO2021098394A1 (zh) 样本分析仪及样本分析方法
JP4593404B2 (ja) 液体試料吸引監視方法及び装置、並びに液体試料分析装置
US5827746A (en) Method to determine the sedimentation of blood and relative device
EP2804003B1 (en) Blood analysis apparatus
JP4648905B2 (ja) 血液学上の分析のための集積装置とそれに関連する方法
CN109959549A (zh) 样本检测方法及样本分析仪
EP3112876B1 (en) Smear preparation appartus and method of washing blood processing unit of the smear preparation apparatus
JP2018096915A (ja) 自動分析装置
CN112119293B (zh) 测定红细胞沉降率及其他相关参数的设备和方法
CN114062205A (zh) 血液细胞分析仪及其清洗方法
CN111886489B (zh) 样本分析仪及样本分析方法
JP2017223656A (ja) シリンジアセンブリ、及び当該シリンジアセンブリの使用方法
CN111812343B (zh) 一种基于免疫比浊法测量的液路系统及其控制方法
CN115541459A (zh) 样本分析仪及样本分析方法
US20240201217A1 (en) Method of washing a fluidic system of an in-vitro diagnostic analyzer
EP4249922A1 (en) Blood sample analyzer and control method therefor
EP4187228B1 (en) System, apparatus, and method for measuring erythrocyte sedimentation rate
CN116067850A (zh) 一种血沉检测方法以及血液分析仪
CN113848342A (zh) 采样针的分血方法和血液细胞分析仪
CN116165108A (zh) 血沉测量系统、设备及血沉测量方法
CN113777009A (zh) 适用于绵羊、山羊和奶牛的细胞分析仪及细胞检测方法
CN118112225A (zh) 血液样本检测方法及血液样本检测设备
JPS58205856A (ja) 自動化学分析装置における吸引吐出装置
JPS6073361A (ja) 分注装置における異常検知装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20889479

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20889479

Country of ref document: EP

Kind code of ref document: A1